Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
Protocol Title: Evaluation of a daily disposable silic one hydrogel multifocal  contact lens in 
myopes and hyperopes 
Protocol CR-6477Version: 2.0Date: 05 January 2022 
Investigational Products : JJVC Investigational Multifocal Contact Lenses manufactured in 
senofilcon A C3 
Keywords:   
Senofilcon A C3, Presbyopia, Daily Wear, Da ily Disposable, Dispensing, Single arm
Statement of Compliance to protocol, GCP and applicable regulatory guidelines:This trial will be conducted in compliance with the protocol, ISO 14155:2020,
1the 
International Council for Harmonization G ood Clinical Practice E6(R2) (ICH GCP),2 the 
Declaration of Helsinki,3 and all applicable re gulatory requirements. 
Confidentiality Statement:This document contains confidential information, which shoul d not be copied, referred to, 
released or published without  written approval from Johnson & Johnson Vision Care, Inc. The 
information may not be disclosed to others except to the extent necessary to obtain Institutional Review Board/Independent Ethics Committee approval and informed consent, or as required by International, Federal and State Laws, as app licable. Persons to whom this information is 
disclosed must be informed that this information is privileged and confidential and that it should not be further disclosed without the written permission of Johnson & Johnson Vision 
Care, Inc. Any supplemental information that  may be added to this document is also 
confidential and proprie tary to Johnson & Johnson Vision Care, Inc. and must be kept in 
confidence in the same manner as the contents of this document. 
CR-6477, v 2.0  
Page 1 of 169JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
TABLE OF CONTENTS
PROTOCOL TITLE, NUMBER, VERSION AND DATE...................................................... 6  
SPONSOR NAME AND ADDRESS....................................................................................... 6  
MEDICAL MONITOR............................................................................................................. 6  
AUTHORIZED SIGNATURES............................................................................................... 7  
CHANGE HISTORY................................................................................................................ 8  
SYNOPSIS....................................................................................................................... ......... 9  
COMMONLY USED ABBREVIATIONS, ACRONYMS AND DEFINITIONS OF TERMS
................................................................................................................................................. 15  
1. INTRODUCTION AND BACKGROUND ................................................................... 17  
1.1. Name and Descriptions of  Investigational Products  Summary of Findings from 
Nonclinical Studies ........................................................................................................... .. 17  
1.2. Intended Use of Inve stigational Products................................................................. 17  
1.3. Summary of Findings from Nonclinical Studies ...................................................... 17  
1.4. Summary of Known Risks and Benefits to Human Subjects ................................... 17  
1.5. Relevant Literature References and Prior Clinical Data Relevant to Proposed Clinical 
Study ......................................................................................................................... ..........17  
2. STUDY OBJECTIVES, ENDPOINTS AND HYPOTHESES ...................................... 19  
2.1. Objectives ................................................................................................................. 19  
2.2. Endpoints .................................................................................................................. 19  
2.3. Hypotheses ............................................................................................................... 20  
3. TARGETED STUDY POPULATION ........................................................................... 22  
3.1. General Characteristics ............................................................................................ 22  
3.2. Inclusion Criteria ...................................................................................................... 22  
3.3. Exclusion Criteria ..................................................................................................... 23  
3.4. Enrollment Strategy.................................................................................................. 24  
4. STUDY DESIGN AND RATIONALE .......................................................................... 24  
4.1. Description of Study Design .................................................................................... 24  
4.2. Study Design Rationale ............................................................................................ 24  
4.3. Enrollment Target and Study Duration .................................................................... 24  
5. TEST ARTICLE ALLOCATION AND MASKING ..................................................... 25  
5.1. Test Article Allocation ............................................................................................. 25  
5.2. Masking .................................................................................................................... 25  
5.3. Procedures for Maintaining and Breaking the Masking........................................... 25  
6. STUDY INTERVENTION ............................................................................................. 26  
CR-6477, v 2.0  
Page 2 of 169JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
6.1. Identity of Test Articles............................................................................................ 26  
6.2. Ancillary ................................................................................................................... 2 6 
6.3. Supplies/Products ..................................................................................................... 26  
6.4. Administration of Test Articles ................................................................................ 27  
6.5. Packaging and Labeling ........................................................................................... 27  
6.6. Storage Conditions ................................................................................................... 27  
6.7. Collection and Storage of Samples .......................................................................... 27  
6.8. Accountability of Test Articles ................................................................................ 27  
7. STUDY EVALUATIONS .............................................................................................. 28  
7.1. Time and Event Schedule ......................................................................................... 28  
7.2. Detailed Study Procedures ....................................................................................... 31  
VISIT 1 ........................................................................................................................... 31  
VISIT 2 ........................................................................................................................... 37  
VISIT 3 ........................................................................................................................... 41  
FINAL EVALUATION .................................................................................................. 43  
7.3. Unscheduled Visits ................................................................................................... 44  
7.4. Laboratory Procedures ............................................................................................. 46  
8. SUBJECTS COMPLETION/WITHDRAWAL.............................................................. 46  
8.1. Completion Criteria .................................................................................................. 46  
8.2. Withdrawal/Discontinua tion from the Study ........................................................... 46  
9. PRE-STUDY AND CONCOMITANT INTERVENTION/MEDICATION ................. 47  
9.1. Systemic Medications .............................................................................................. 47  
10. DEVIATIONS FROM THE PROTOCOL .................................................................. 47  
11. STUDY TERMINATION ........................................................................................... 48  
12. PROCEDURE FOR HANDLING PRODUCT QUALITY COMPLAINTS .............. 49  
13. ADVERSE EVENTS ................................................................................................... 50  
13.1.  Definitions and Classifications ............................................................................. 50  
13.2.  Assessing Adverse Events .................................................................................... 52  
13.2.1.  Causality Assessment .................................................................................... 52  
13.2.2.  Severity Assessment ...................................................................................... 53  
13.3.  Documentation and Follow-Up of Adverse Events .............................................. 53  
13.4.  Reporting Adverse Events .................................................................................... 55  
13.4.1.  Reporting Adverse Events to Sponsor .......................................................... 55  
CR-6477, v 2.0  
Page 3 of 169JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
13.4.2.  Reporting Adverse Events to the Respons ible IEC/IRB and Health Authorities
 ........................................................................................................................56  
13.5.  Event of Special Interest ....................................................................................... 56  
13.6.  Reporting of Pr egnancy ........................................................................................ 56  
14. STATISTICAL METHODS ........................................................................................ 56  
14.1.  General Considerations ......................................................................................... 56  
14.2.  Sample Size Justification ...................................................................................... 57  
14.3.  Analysis Populations ............................................................................................ 60  
14.4.  Level of Statistical Significance ........................................................................... 60  
14.5.  Primary Analysis .................................................................................................. 61  
14.6.  Secondary Analysis .............................................................................................. 65  
14.7.  Other Exploratory Analysis .................................................................................. 67  
14.8.  Interim Analysis ................................................................................................... 68  
14.9.  Procedure for Handling Missi ng Data and Drop-Outs ......................................... 68  
14.10.  Procedure for Reporting Deviati ons from Statistical Plan ................................... 68  
15. DATA HANDLING AND RECORD KEEPING/ARCHIVING ................................ 68  
15.1.  Electronic Case Report Form/Data Collection ..................................................... 68  
15.2.  Subject Record ...................................................................................................... 69  
15.3.  Trial Registration on Cl inicalTrials.gov ............................................................... 69  
16. DATA MANAGEMENT............................................................................................. 69  
16.1.  Access to Source Data/Document ........................................................................ 69  
16.2.  Confidentiality of Information.............................................................................. 69  
16.3.  Data Quality Assurance ........................................................................................ 70  
16.4.  Data Monitoring Committee (DMC) .................................................................... 70  
17. CLINICAL MONITORING ........................................................................................ 70  
18. ETHICAL AND REGULATORY ASPECTS ............................................................ 71  
18.1.  Study-Specific Design Considerations ................................................................. 71  
18.2.  Investigator Responsibility ................................................................................... 71  
18.3.  Independent Ethics Committee or Ins titutional Review Board (IEC/IRB) .......... 71  
18.4.  Informed Consent ................................................................................................. 72  
18.5.  Privacy of Personal Data ...................................................................................... 73  
19. STUDY RECORD RETENTION................................................................................ 74  
20. FINANCIAL CONSIDERATIONS ............................................................................ 74  
21. PUBLICATION ........................................................................................................... 75  
CR-6477, v 2.0  
Page 4 of 169JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
22. REFERENCES ............................................................................................................ 75  
APPENDIX A: PATIENT REPORTED OUTCOMES (STUDY QUESTIONNAIRES) ..... 77  
APPENDIX B: PATIENT INSTRUCTION GUIDE ........................................................... 100  
APPENDIX C: PACKAGE INSERT (APPROVED PRODUCT) ....................................... 101  
APPENDIX D: PRESBYOPIC SY MPTOMS QUESTIONNAIRE .................................... 102  
APPENDIX E: OCULAR DOMINANCE ........................................................................... 103  
APPENDIX F: LENS FITTING GUIDE ............................................................................. 104  
APPENDIX G: BINOCULAR OVER REFRACTION ....................................................... 106  
APPENDIX H:  .................................... 107  
, Determination of Near Addition ........................................................................ 108  
, Near LogMAR Visual Acuity  Measurement Procedure .................................... 114  
, Lens Fitting Characteristics ................................................................................ 117  
, Subject Reported Ocular Symptoms/Problems .................................................. 123  
, Determination of Distance Sphero cylindrical Refractive Error ......................... 125  
, Biomicroscopy Scale .......................................................................................... 131  
, Distance and Near Snellen Vi sual Acuity Evaluation ........................................ 137  
, Distance LogMAR Visual Acuity Measurement Procedure .............................. 142  
, Patient Reporte d Outcomes ................................................................................ 146  
, Visual Acuity Chart Luminance and Room Illumination Testing ..................... 148  
APPENDIX I: GUIDELINES FOR COVID-19 RISK MITIGATION ................................ 157  
PROTOCOL COMPLIANCE INVESTI GATOR(S) SIGNATURE PAGE ........................ 169  
LIST OF TABLES
Table 1: Test Articles ........................................................................................................ ...... 26  
Table 2: Ancillary Supplies ................................................................................................... . 27 
Table 3: Time and Events ...................................................................................................... . 28 
Table 4: Disallowed syst emic medications ............................................................................. 47  
Table 5: Examples of major and minor protocol deviations ................................................... 48  
Table 6: Historical Studi es Utilized for Sample Size Calculations ........................................ 57  
Table 7: Historical Data by Endpoint ..................................................................................... 58  
Table 8: Sample Size Estimates by Endpoint ......................................................................... 59  
Table 9: Clinical Studies Planned to be Utilized in Exploratory Meta-Analysis ................... 67  
CR-6477, v 2.0  
Page 5 of 169JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
SYNOPSIS 
Protocol Title Evaluation of a daily disposable silicone hydrogel multifocal 
contact lens in myopes and hyperopes
Sponsor JJVC, 7500 Centurion Pa rkway, Jacksonville, FL  32256
Clinical Phase Clinical trial phase: Design Validation Study
Design control phase:  Phase 3
Trial Registration This study will be registered on ClinicalTrials.gov.
Test Article(s) Investiga tional Product:  JJVC Inve stigational Multifocal 
Contact Lenses manufactured in senofilcon A C3
Wear and Replacement 
SchedulesWear Schedule: The test lenses will be used on a daily disposable basis.   Replacement Schedule: The lenses will be replaced after a day of wear.
Objectives The objective of this study is to demonstrate that the JJV 
Investigational senofilcon A C3 Multifocal Contact Lens in its final lens design made in th e 4GT Manufacturing Platform 
meets the validation requirements related to objective and subjective vision, eye health and fit acceptance.  
Study Endpoints Primary Endpoints
xCLUE vision scores 
xLogMAR visual acuity scores  
xUnacceptable lens fit (Yes/No)
xGrade 3 or Higher Biomicroscopy Findings (Yes/No) 
Secondary Endpoints 
xNumber of lenses needed to fit (optimize) the subject’s vision 
xCLUE comfort scores
xCLUE handling scores 
Study Design This is a single-masked, si ngle-arm, dispensing clinical trial. 
Up to 120 subjects will be enrolled into the study with the aim of completing approximately 100 subjects.  The subjects will 
be fit at (Visit 1) in the study lens and wear the lens for 3±1 day then undergo optimization (Visit 2) and wear the optimized pair for approximately 1 week (7±1 day). At the follow-up visit (Visit 3), logMAR acuity and final subjective responses will be collected and the subject will be exited from the study.   
See the flow chart at the end of the synopsis table for the 
schematic of the study visits  and procedures of main 
observations (Figure 1).
CR-6477, v 2.0  
Page 9 of 169JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
Sample Size Approximately 120 eligible subjects will be enrolled (72 
myopes and 48 hyperopes) with 100 subjects targeted to 
complete (60 myopes and 40 hyperopes).
Study Duration The study will last approximately 2 to 3 months.
Anticipated Study Population Healthy male and female volunteers with presbyopia will be screened as per criteria outlined below.  All volunteers will have baseline measurements taken to ensure eligibility.  The baseline procedures will occur after informed consent has been obtained.  Subjects will have medical and contact lens history recorded, baseline questionnaires completed, and 
refractive and anterior segment st atus determined.  For a detail 
flowchart of procedures below .
CR-6477, v 2.0  
Page 10 of 169JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
Eligibility Criteria -
Inclusion Potential subjects must satisfy all of the following criteria to be enrolled in the study 
Inclusion Criteria after Screening:
The subject must: 
1. Read, understand, and sign the STATEMENT OF 
INFORMED CONSENT and receive a fully executed copy of the form.
2. Appear able and willing to adhere to the instructions 
set forth in this clinical protocol.
3. Be at least 40 years of age and not greater than 70 years 
of age at the time of consent.
4. Own a wearable pair of spectacles if required for their 
distance vision.
5. Be an adapted soft contact lens wearer in both eyes 
(i.e. worn lenses a minimum of 2 days per week for at least 6 hours per wear day, for 1 month or more duration). 
6. Either already be wearing a presbyopic contact lens 
correction (e.g., reading spectacles over contact lenses, multifocal or monovi sion contact lenses, etc.) 
or if not respond positively to at least one symptom on the “Presbyopic Symptoms Questionnaire”. 
Inclusion Criteria at Baseline:
7. The subject’s distance spherical equivalent refraction 
YHUWH[FRUUHFWHGLI -4.25 D) must be in the range of 
-1.25 D to -5.75 D or +0.75 D to +3.25 D in each eye. 
8.7KHVXEMHFW¶VUHIUDFWLYHF\ OLQGHUPXVWEH'LQ
each eye.
9. The subject’s ADD power must be in the range of 
+0.75 D to +2.50 D. 
10. The subject must have distance best corrected visual 
acuity of 20/20
-3or better in each eye.
CR-6477, v 2.0  
Page 11 of 169JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
Eligibility Criteria –
Exclusion Potential subjects who meet any of the following criteria will be excluded from participating in the study:  
Exclusion Criteria after Screening:
The subject must not: 
1. Be currently pregnant or lactating. 2. Have any active or ongoi ng ocular or systemic 
allergies that may interfere with contact lens wear.  
3. Have any active or ongoing systemic disease, 
autoimmune disease, or use of medication, which may interfere with contact lens wear. This may include, but not be limited to, diabetes, hyperthyroidism, Sjögren’s syndrome, xerophthalmia, acne rosacea, Stevens-Johnson syndrome, and immunosuppressive diseases or any infectious diseases (e.g. hepatitis, tuberculosis).
4. Have any previous, or pla nned, ocular or intraocular 
surgery (e.g. radial keratotomy, PRK, LASIK, lid procedures, dacryocystorhinostomy, peripheral iridotomy/iridectomy, cat aract surgery, retinal 
surgery, etc.). 
5. Have a history of amblyopia, strabismus or binocular 
vision abnormality. 
6. Use of any of the following medications within 1 week 
prior to enrollment: oral retinoid, oral tetracyclines, anticholinergics, oral phenothiazines, oral/inhaled corticosteroids.  See sec tion 9.1 for further examples.
7. Use of any ocular medication, with the exception of 
rewetting drops. 
8. Have a history of herpetic keratitis.9. Have a history of irregular cornea.10. Have a history of pathological dry eye. 11. Have Participated in any contact lens or lens care 
product clinical trial with in 30 days prior to study 
enrollment.
12. Be and employee or immediate family member of an 
employee of clinical site (e.g., Investigator, Coordinator, Technician). 
13. Have any known hypersensitivity  or allergic reaction 
to non-preserved rewetting drop solutions or sodium fluorescein.
Exclusion Criteria at Baseline:The subject must not: 
CR-6477, v 2.0  
Page 12 of 169JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
14. Have clinically significant (Grade 2 or greater) corneal 
edema, corneal vasculariza tion, corneal staining, tarsal 
abnormalities or bulba r injection, or any other corneal 
or ocular abnorma lities which would contraindicate 
contact lens wear.
15. Have any current ocular infection or inflammation. 
16. Have any current ocul ar abnormality that may 
interfere with contact lens wear.
Disallowed 
Medications/Interventions  Use of any prescription or over-the-counter (OTC) medications that may affect contact lens wear. See section 9.1 in the protocol for details regarding disallowed systemic medications.
Measurements and ProcedureslogMAR acuity, subjective re sponses, biomicroscopy and fit 
evaluations. 
Microbiology or Other Laboratory TestingNone
Study Termination The occurrence of one or more Unanticipated Adverse Device 
Effect (UADE), or any serious adverse event (SAE) where relationship to study agent cannot be ruled out, may result in stopping further dispensing inves tigational product. In the 
event of a UADE or SAE, the Sponsor Medical Monitor may unmask the treatment regimen of  subject(s) and may discuss 
this with the Principal Investigator before any further subjects are enrolled.
Ancillary Supplies/ Study-Specific MaterialsNon-Preserved Rewetting drops, lens cases, glass vials, saline, ETDRS light cabinet, 4 M logM AR charts, and Near logMAR 
charts.
Principal Investigator(s) and Study Institution(s)/Site(s)A full list of Principal Investigators, clinical sites, and institutions is kept separately from the St udy Protocol and is 
included in the study Trial Master File.
CR-6477, v 2.0  
Page 13 of 169JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
COMMONLY USED ABBREVIATIONS, ACRONYMS AND DEFINITIONS OF 
TERMS
ADD   Plus Power Required For Near Use 
ADE   Adverse Device EffectAE   Adverse Event/Adverse Experience BCVA   Best Corrected Visual AcuityBSCVA  Best Spectacle Corrected Visual AcuityCFR   Code of Federal Regulations CLUE   Contact Lens User ExperienceCOAS   Complete Ophthalmic Analysis SystemCOM   Clinical Operations ManagerCOVID-19  Coronavirus Disease 2019 CRA   Clinical Research AssociateCRF   Case Report FormCRO   Contract Research OrganizationCT   Center Thickness
   
D   Diopter DMC   Data Monitoring CommitteeeCRF   Electronic Case Report FormEDC   Electronic Data CaptureETDRS  Early Treatment Diabetic Retinopathy Study
FDA   Food and Drug Administration GCP   Good Clinical PracticeHIPAA  Health Insurance Portability and Accountability Act IB   Investigator’s Brochure ICF   Informed Consent Form ICH   International Conference on Harmonization IDE   Investigational Device ExemptionIEC   Independent Ethics Committee IRB   Institutional Review BoardISO   International Organization for Standardization ITT   Intent-to-TreatJJVC   Johnson & Johnson Vision Care, Inc. LC   Limbus Center LogMAR  Logarithm of Minimal Angle of Resolution MedDRA
©  Medical Dictionary for Regulatory Activities
MOP   Manual of Procedures NAVQ   Near Activity Visual QuestionnaireNIH   National Institutes of HealthOD   Right Eye OHRP   Office for Human Research Protections OHSR   Office for Human Subjects ResearchOS   Left EyeOU   Both Eyes 
CR-6477, v 2.0  
Page 15 of 169JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
PD   Protocol Deviation 
PHI   Protected Health InformationPI   Principal InvestigatorPIG   Patient Instruction Guide PQC   Product Qu ality Complaint 
PRO   Patient Reported Outcome QA   Quality Assurance QC   Quality Control SAE   Serious Adverse Event/Serious Adverse Experience SAP   Statistical Analysis PlanSAS   Statistical Analysis SystemSD   Standard Deviation SOP   Standard Operating Procedure UADE   Unanticipated Adverse Device EffectUSADE  Unanticipated Serious Adverse Device EffectVA   Visual Acuity
CR-6477, v 2.0  
Page 16 of 169JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
In  30 subjects completed the study per the protocol.  The lenses displayed good 
clinical vision performance with  binocular, high luminance, hi gh contrast logMAR visual 
acuity of -0.057 and 0.091 at distance and near  respectively. There was one adverse event 
reported during the study.  The subject experi enced mild upper respiratory virus and did not 
receive any treatment for this event.  The even t resolved and the subject completed the study.  
The investigator considered the event to be unrelated related to  study article/procedure.6
In  41 subjects completed the study per the protocol.  The lenses displayed good 
clinical vision performance with  binocular, high luminance, hi gh contrast logMAR visual 
acuity of -0.104 and 0.058 at distance and near respectively. There were no adverse events 
reported during the study.7    
In  67 subjects completed the study per the protocol.  The lenses displayed good 
clinical vision performance with  binocular, high luminance, hi gh contrast logMAR visual 
acuity of -0.078 and 0.062 at distance and near respectively.  There were six adverse of 
events during the study.  Two of the six were ocular adverse events were related to the 
control lens.  Both were corn eal infiltrative events; one was non-significant and the other was 
significant and both were cla ssified as possibly related to the contact lenses.9   
 was a single masked, randomized controlle d, dispensing clinical trial and had a 
primary endpoint of logMAR visual acuity.  Th ere were 60 subjects that completed the study 
per the protocol.  The lenses displayed good c linical vision performance with binocular, high 
luminance, high contrast logMAR visual acuity of -0.132, -0.066 and 0.072 at distance, 
intermediate and near respectively.  There were four adverse of events during the study.  
Three of the four were non-ocular adverse ev ents.  Two of those not related to the study 
lenses and one (headache) was related to the Control Contact lens.  There was one ocular 
adverse event (non-significant infiltrative event) that was possibly related to the test lens.10   
 was a single masked, randomized controlle d, dispensing clinical trial on hyperopic 
presbyopes and had a primary endpoint of logMAR visual acuity.  There were 64 subjects that completed the study per the protocol.  The lenses displayed good clinical vision 
performance with binocular, high luminance, high  contrast logMAR visual acuity of -0.083, -
0.013 and 0.090 at distance, intermediate and near respectively.  There were four adverse of 
events during the study.  Three of the four were  non-ocular adverse events.  None of the non-
ocular adverse events were related to the test articles.  There was one ocular adverse event (non-significant) that was mild corneal staining that was not related to the test lens.
101  
 was a single masked, randomized controlled, dispensing, 3x3 crossover clinical 
trial on hyperopic presbyopes a nd had a primary endpoint of subjective vision responses.  
There were 34 subjects that completed the study per the protocol.  The lenses displayed good 
clinical vision performance with  binocular, high luminance, hi gh contrast logMAR visual 
acuity of -0.10, -0.04 and 0.06 at distance, intermed iate and near respectively.  There were no 
adverse events reported during the study.12   
 was a single masked, randomized controlled, dispensing clinical trial on myopic 
presbyopes and had a primary endpoint of logMAR visual acuity.  There were 66 subjects 
CR-6477, v 2.0  
Page 18 of 169JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
that completed the study per the protocol.  The lenses displayed good clinical vision 
performance with binocular, high luminance, high  contrast logMAR visual acuity of -0.128, -
0.061 and 0.057 at distance, intermediate and near  respectively.  There was one adverse of 
event during the study.  The one ocular adverse event was a non-significant grade 2 or less 
slit lamp finding requiring treatment.  The event was classified as related and occurred while wearing the control lens.
13
For information about the Investigational product refer to the CR-6477 Investigational Brochure. 
2. STUDY OBJECTIVES, ENDPOINTS AND HYPOTHESES
2.1. Objectives 
Primary Objective:
The objective of this study is to demonstrate that the JJV Investigational senofilcon A C3 
Multifocal Contact Lens in its final lens design made in the 4GT Manufacturing Platform meets the validation requirements re lated to objective and subjectiv e vision, eye health and fit 
acceptance.
Secondary Objective:
The secondary objective of this study is to dete rmine that the lenses meet the users’ needs in
overall subjective vision, lens handli ng, comfort and lens fit success.  
2.2. Endpoints 
Primary Efficacy Endpoints: 
Visual Performance (logMAR)
Visual Performance will be a ssessed binocularly at the 1-week follow-up evaluation under high 
luminance high contrast conditions. At distance (4 meters), VA is assessed using ETDRS 
Charts; while near (40 cm) and intermediate (64 cm) assessments will be made using reduced Guillon-Poling charts. See  in Appendix H for details 
regarding the collection of visual acuity (logMAR) visual ability.
Subjective Vision  
Subjective vision will be assessed using the Contact Lens User Experience (CLUE™) 
questionnaire at the 1-week follow-up evalua tion. CLUE™ is a validated patient-reported 
outcomes questionnaire to  assess patient-experience attributes  of soft, disposable contact 
lenses (comfort, vision, handling, and packaging) in a contact-lens wearing population in the 
US, ages 18-65.  Derived CLUE™ scores using Item Response Theory (IRT) follow a normal 
distribution with a population average score of 60 (SD 20), where higher scores indicate a more 
favorable/positive response with a range of 0-120.   A 5-point increase in an average CLUE™ 
score translates into 10% shift in the distribu tion of scores for populati on of soft contact lens23. 
CR-6477, v 2.0  
Page 19 of 169JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
Primary Safety Endpoints:
Slit Lamp Findings (SLF) 
Slit Lamp Findings (Grade 3 or higher) will be assessed for each s ubject eye at all study visits 
(schedule and unscheduled). SLFs will be evaluated and classified using the FDA Grading 
scale rating from 0 to 4, where Grade 0 represents the absence of findings and 1 to 4 
representing successively worse findings (i.e. Grade 1=trace, Grade 2= mile, Grade 
3=moderate and Grade 4= severe). The percentage  of eyes with Grade 3 or higher slit lamp 
findings will be analyzed and will include corneal infiltrates. See in Appendix H 
for more details on the collect of SLFs.  
Unacceptable Lens Fit 
Unacceptable lens fit will be a ssessed at all study visits (scheduled and unscheduled) for each 
subject eye. Unacceptable fit is a binary respons e where Y=1 if lens fit is unacceptable and 
Y=0 otherwise. Unacceptable fit was defined as unacceptable if any one of the following 
criteria:
• limbal exposure at primary gaze or with extreme eye movement; 
• edge lift;
• excessive movement in primary up gaze; 
• insufficient movement in all three of the following conditions: primary gaze, up gaze, 
and push up test. 
Eyes with multiple unacceptable fitting events was counted only once. See  in 
Appendix H for additional details regarding lens fit assessments.
Secondary Endpoints 
xCLUETM Vision score  
xCLUETMComfort score
xCLUETM Handling core
xLens Fit Success (Number of lenses needed to fit (optimize) the subject’s vision) 
2.3. Hypotheses
Co-Primary Safety Hypotheses 
1. When wearing the Test lenses, the proporti on (%) of eyes with at least one reported 
clinically significant slit-lamp finding (Grade 3 or 4) during the post-fit period will be 
statistically less than 5%.  
2. When wearing the Test lenses, the proporti on (%) of eyes with an unacceptable fit 
during the study will be sta tistically less than 5%.
CR-6477, v 2.0  
Page 20 of 169JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
Both co-primary safety hypotheses must be met in order to test any co-primary efficacy 
hypotheses.   
Co-Primary Efficacy Hypotheses: 
1. After approximately 1-week of wear in the optimized Test lenses, the mean overall 
quality of vision score of the Test lenses will be statistically better than 41 points for 
the myope population.  This will be recorded by the subject using the CLUE Follow-up Questionnaire. 
2. After approximately 1-week of wear in the optimized Test lenses, the mean overall 
quality of vision score for the Test lenses will be statistically better than 36 points for the hyperope population. This will be recorded by the subject using the CLUE 
Follow-up Questionnaire. 
3. After approximately 1-week of wear in the optimized Test lenses, the mean distance, 
binocular, high luminance, high contrast logMAR  visual acuity score of the Test lens 
will be statistically lower than 0.0 logMAR. 
4. After approximately 1-week of wear in the optimized Test lenses, the mean 
intermediate, binocular, high luminance, high contrast logMAR visual acuity score of 
the Test lens will be statistically lower than 0.17 logMAR.
5. After approximately 1-week of wear in the optimized Test lenses, the mean near, 
binocular, high luminance, high contrast logMAR  visual acuity score of the Test lens 
will be statistically lower than 0.17 logMAR.
All safety and efficacy co-pr imary hypotheses must be satisfied in order to meet the 
study objectives and to test any secondary hypotheses. 
Secondary Hypotheses 
1. After approximately 1-week of wear in the optimized Test lenses, the mean overall 
quality of vision score of the Test lenses will be statistically better than 46 points for 
the myope population.  This will be recorded by the subject using the CLUE Follow-up Questionnaire. 
2. After approximately 1-week of wear in the optimized Test lenses, the mean overall 
quality of vision score for the Test lenses will be statistically better than 41 points for 
CR-6477, v 2.0  
Page 21 of 169JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
the hyperope population.  This will be reco rded by the subject using the CLUE Follow-
up Questionnaire. 
3. After approximately 1-week of wear in the optimized Test lenses, the mean overall 
comfort score for the Test lenses will be statistically better than 52 points.  This will be 
recorded by the subject using the CLUE Follow-up Questionnaire.   
4. After approximately 1-week of wear in the optimized Test lenses, the mean overall 
handling score for the Test lenses will be statistically better than 53 points.  This will be recorded by the subject using the CLUE Follow-up Questionnaire.  
5. The percentage of subjects who obtain the optimum lens pair in 4 lenses or less will be 
statistically better than  90%. 
3. TARGETED STUDY POPULATION
3.1. General Characteristics 
Healthy male and female subjects who are habitual soft contact le ns wearers will be recruited.  
Subjects will be at least 40 years of age and not older than 70 years of age. Subjects enrolled in this study will be either myopi c or hyperopic and have presbyopia .    
3.2. Inclusion Criteria
Potential subjects must satisfy all the follo wing criteria to be enrolled in the study: 
Inclusion Criteria after Screening:The subject must: 
1. Read, understand, and sign the STATEMENT OF INFORMED CONSENT and 
receive a fully executed copy of the form.
2. Appear able and willing to adhere to the instructions set forth in this clinical protocol. 3. Be at least 40 years of age and not greater than 70 years of age at the time of consent.4. Own a wearable pair of spectacles if required for their distance vision.5. Be an adapted soft contact lens wearer in  both eyes (i.e. worn lenses a minimum of 2 
days per week for at least 6 hours per w ear day, for 1 month or more duration). 
6. Either already be wearing a presbyopic contact  lens correction (e.g., reading spectacles 
over contact lenses, multifocal or monovision contact lenses, etc.) or if not respond positively to at least one symptom on th e “Presbyopic Symptoms Questionnaire”. 
Inclusion Criteria at Baseline:
7. TKHVXEMHFW¶VGLVWDQFHVSKHULFDOH TXLYDOHQWUHIUDFWLRQYHUWH[F RUUHFWHGLI -4.25 D) 
must be in the range of -1.25 D to -5.75 D or +0.75 D to +3.25 D in each eye. 
8.7KHVXEMHFW¶VUHIUDFWLYHF\OLQGHUPXVWEH'LQHDFKH\H
CR-6477, v 2.0  
Page 22 of 169JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
9. The subject’s ADD power must be in the range of +0.75 D to +2.50 D. 
10. The subject must have distance be st corrected visual acuity of 20/20-3or better in each 
eye.
3.3. Exclusion Criteria
Potential subjects who meet any of the following criteria will be excluded from participating in the study:  
Exclusion Criteria after Screening:
The subject must not: 
1. Be currently pregnant or lactating. 2. Have any active or ongoing ocular or systemic allergies that may interfere with contact 
lens wear.  
3. Have any active or ongoing systemic disease, autoimmune disease, or use of 
medication, which may interfere with contact lens wear. This may include, but not be 
limited to, diabetes, hyperthyroidism, Sj ögren’s syndrome, xerophthalmia, acne 
rosacea, Stevens-Johnson syndrome, and immunosuppressive diseases or any 
infectious diseases (e.g. hepatitis, tuberculosis). 
4. Have any previous, or pla nned, ocular or intraocular su rgery (e.g. radial keratotomy, 
PRK, LASIK, lid procedures, da cryocystorhinostomy, peripheral 
iridotomy/iridectomy, cataract su rgery, retinal surgery, etc.). 
5. Have a history of amblyopia, strabi smus or binocular vision abnormality. 
6. Use of any of the following medications within 1 week prior to enrollment: oral 
retinoid, oral tetracyclines, anticholiner gics, oral phenothiazines, oral/inhaled 
corticosteroids.  See sec tion 9.1 for further examples.
7. Use of any ocular medication, w ith the exception of rewetting drops. 
8. Have a history of herpetic keratitis.
9. Have a history of irregular cornea.10. Have a history of pathological dry eye. 11. Have Participated in any contact lens or lens care pr oduct clinical trial within 30 days 
prior to study enrollment. 
12. Be and employee or immediate family member of an employee of clinical site (e.g., 
Investigator, Coordinator, Technician). 
13. Have any known hypersensitivity  or allergic reaction to  non-preserved rewetting drop 
solutions or sodium fluorescein. 
Exclusion Criteria at Baseline:The subject must not: 
14. Have clinically significant (Grade 2 or greater) corneal edema, corneal vascularization, 
corneal staining, tarsal abnormalities or bulbar injection, or any other corneal or ocular abnormalities which would contra indicate contact lens wear.
15. Have any current ocular infection or inflammation. 
CR-6477, v 2.0  
Page 23 of 169JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
16. Have any current ocular a bnormality that may interfere with contact lens wear.  
3.4. Enrollment Strategy
Study subjects will be recruited from the Instituti on/clinical site’s subject database and/or 
utilizing Independent Ethics Committee (IEC) or Institutional Review Board (IRB) approved 
materials. 
4. STUDY DESIGN AND RATIONALE
4.1. Description of Study Design
This is a single-masked, single-arm, dispensing clinical trial. Up to  120 subjects (72 myopes 
and 48 hyperopes) will be enrolle d into the study with the aim of completing approximately 
100 subjects (60 myopes and 40 hyperopes).   
The study begins with an initial visit, Visit 1 (Day 0), if a subject is found to meet all eligibility
criteria, they will be fit with the study lens, in both eyes; otherwise, the subject will be deemed
ineligible and classified as a screen failure.
If a subject is dispensed lenses at the initial vis it, then two additional vi sits will be conducted. 
Visit 2 will occur 3 ± 1 days after Visit 1. At Visit 2 subjects will undergo lens optimization if 
the subject reports unsatisfactory vision or is una ble to obtain 20/30 binoc ular distance visual 
acuity with the study lenses. Subjects will return for Visit 3 (Final Evaluation) after 12±2 days. At the final visit, subjects will undergo subjective and objective assessments of vision. 
Subjects will be advised to wear the study lenses  every day while they are in the study for a 
minimum of 6 hours per day. The study lens will be replaced at the optimization visit. 
However, lost or damaged lenses maybe repla ced when necessary. Unscheduled visit may be 
conducted. 
4.2. Study Design Rationale 
The study is intended to compare one study lens type and to characterize performance against 
predefined targets which are set in the Customer Requirements Document.  Due to the 
predefined performance criteria a single-arm st udy design was chosen.  The specifics of the 
lens design, beyond that the lenses are intended to  correct for their dist ance and near vision, 
will be masked to the subject.  The final optimized lenses are dispensed for approximately 1 week of daily disposable wear which is the intended modality of the lenses.
4.3. Enrollment Target and Study Duration
A total of approximately 120 e ligible subjects will be enrolle d (72 myopes and 48 hyperopes)  
with 100 subjects targeted to complete (60 m yopes and 40 hyperopes).  Th e study is anticipated 
to last 2-3 months. 
CR-6477, v 2.0  
Page 24 of 169JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
5. TEST ARTICLE ALLOCATION AND MASKING
5.1. Test Article Allocation 
The study lenses will be worn in a bilateral fashion using a single-arm design.  Due to the 
nature of the design no randomization is required.   
5.2. Masking
This is a single arm study and all subjects will be assigned to the same  study lens. Subjects 
will be unaware of the identity of the investiga tional product. Investigat ors and clinical site 
personnel involved in the data co llection will not be masked, however, the identity of the test 
device will be masked.   
Under normal circumstances, the mask should not be broken until all subj ects have completed 
the study and the database is finalized. Otherwise, the mask s hould be broken only if specific 
emergency treatment/course of ac tion would be dictated by knowing the treatment status of the 
subject. In such cases, the Investigator may, in an emergency, contact the medical monitor.  In 
the event the mask is broken, the Sponsor must be informed as soon as possible. The date, 
time, and reason for the unmasking must be documented in the subject record.  
5.3. Procedures for Maintaining  and Breaking the Masking
The identity of the test article shall not be broken unless information concerning the lens type is necessary for the urgent medical treatment of  a subject. The Sponsor must be notified before 
the mask is broken. 
Investigator or designee will pull the appropria te test articles from th e study supply. All test 
articles that are opened, whether dispensed (place d/fit on eye or dispensed outside the clinical 
site) or not, must be recorded on the Test Article Accountability L og in the “Dispensed” 
section.
CR-6477, v 2.0  
Page 25 of 169JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
7.4. Laboratory Procedures 
Not Applicable 
8. SUBJECTS COMPLETION/WITHDRAWAL 
8.1. Completion Criteria
Subjects are considered to have  completed the study if they:  
xprovided informed consent. 
xthey are eligible.
xcompleted all study visits
8.2. Withdrawal/Discontinuation from the Study
A subject will be withdrawn from the study for any of the following reasons: 
xSubject withdrawal of consent. 
xSubject not compliant to protocol  
xSubject lost to follow-up. 
xSubject no longer meets eligibility criteri a (e.g. the subject becomes pregnant).
xSubject develops significant or serious adverse events necessitating discontinuation of 
study lens wear  
xSubjects who have experienced a Corneal Infiltrative Event (CIE). 
xInvestigator’s clinical judgment regarding the subject safety reasons (that it is in the 
best interest of the subject to stop treatment).
xSubject not compliant with study lens wear schedule 
xSubject not successfully dispensed due to lack of efficacy and safety including poor 
vision, poor comfort or unacceptable fit. 
For discontinued subjects, the Investigator will: 
xComplete the current visit (scheduled or unscheduled). 
xComplete the Final Evaluation, indicating th e reason that the subject was discontinued 
from the study. 
xRecord the spherocylindrical refraction with best corrected distance visual acuity. 
xCollect used test article(s) (worn or brought to the visit) from the subject and discard 
them, unless otherwise stated in section 7.2. 
xCollect all unused test article(s) from the subject. 
xMake arrangements for subject care, if needed, due to their study participation 
Additional subjects will be enrolled if a subj ect discontinues from the study prematurely.  
In cases where a subject is lost to follow-up, ever y possible effort must be made to contact the 
subject and determine the reason for discontinua tion/withdrawal. The measures taken to follow 
up must be documented including two written attempts and a certified letter (or equivalent) as 
the final attempt. 
CR-6477, v 2.0  
Page 46 of 169JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
JJVC (and the IEC/IRB and DMC, if applicable) will evaluate all adverse events. If it is 
determined that an adverse event presents an unr easonable risk, the investigation, or that part 
of the investigation presenting the risk, will be terminated as soon as possible. 
Should the study be terminated (either prematurely or as scheduled), the Investigator will notify the IEC/IRB and Regulatory Authority as  required by local regulatory requirements. 
12. PROCEDURE FOR HANDLING PRODUCT QUALITY COMPLAINTS
A Product Quality Complaint (PQC ) refers to any written, electr onic, or oral communication 
that alleges deficiencies related to the identity, quality, durability, reliability, safety, 
effectiveness or performance of test articles after they have been released for clinical trial use.  
Potential complaints may come from a variety of sources including but not limited to subjects, 
clinical research associates (CRA), clinical  operations managers (COM), medical monitors, 
and site personnel, etc. The following are not considered product quality complaints: 
xSubject satisfaction inquirie s reported via “Subjective Qu estionnaires” and “Patient 
Reported Outcomes (PRO).” 
xClinical test articles that are stored improperly or damaged after receipt at the investigational site.
xLens replacements that occur due to drops/fall-outs. 
xDamage deemed by clinicians or clinical staff to be caused by handling by the user, 
and not indicative of a quality deficiency (i.e. tears, rips, etc.), only in situations where there is no deficiency alleged by the subject. 
Within 24 hours of site personnel becoming aware that a PQC has occurred, the PQC must be 
recorded in the EDC system, which will trigger an automatic email notification to the appropriate COM/CRA and Clinical QA representative. In cases where the EDC system in use is not configured to send automatic notificati ons or when an EDC system is not used, the 
COM/CRA is responsible for notifying Clinical QA upon discovery that a PQC has occurred.   
Upon receipt of the EDC notification, the COM/ CRA will contact the study site to collect 
additional information which will include: 
xDate the complaint was received/recorde d in the EDC System (Date of Sponsor 
Awareness). 
xWho received the complaint. 
xStudy number. 
xClinical site information (contact name, site ID, telephone number). 
xLot number(s). 
xUnique Subject Identifier(s). 
xIndication of who first observed co mplaint (site personnel or subject). 
xOD/OS indication, along with whet her the lens was inserted. 
xAny related AE number if applicable. 
CR-6477, v 2.0  
Page 49 of 169JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
xDetailed complaint description (scheduled/unscheduled visit, wear time, symptoms, 
resolution of symptoms, etc.). 
xEye Care Provider objective (slit lamp) findings if applicable. 
xConfirmation of product availa bility for return (and tracking information, if available), 
or rationale if product is not available for return 
Once a complaint is received, it will be assessed by the COM, CRA, or trained site personnel to determine if it is an Adverse Event/Seri ous Adverse Event (AE/SAE). If the complaint 
results in an AE/SAE, the COM/CRA, or traine d site personnel will follo w section 13 of this 
protocol. If the AE/SAE was potentially the result of a product quality related deficiency, these procedures also apply and will be executed in parallel.  
In some cases, a PQC form may be generated in EDC by the site in error. In this event, the 
PQC forms will be marked “Intentionally Left Blank” or “ILB”.  Justification for ILB must be documented. 
13. ADVERSE EVENTS
13.1. Definitions and Classifications
Adverse Event (AE) – An AE is “any untoward medical occurrence, unintended disease or 
injury, or untoward clinical signs (including a bnormal laboratory findings) in subjects, users 
or other persons, whether or not related to the investig ational medical device.”  
Note : This definition includes events related to the investigational medical device or the 
comparator, and to the procedures involved. Fo r users or other persons, this definition is 
restricted to events related to investigational medical devices.
An AE includes any condition (including a pre-existing condition) that: 
1. Was not present prior to the study, but app eared or reappeared following initiation of 
the study. 
2. Was present prior to the study but worsen ed during the study. This would include any 
condition resulting from concomita nt illnesses, reactions to  concomitant medications, 
or progression of disease states. 
Note : Pregnancy must be documented as an adverse event and must be reported to the clinical 
monitor and to the Sponsor immedi ately upon learning of the event. 
Serious Adverse Event (SAE) – An SAE is any adverse event that led to any of the following: 
xDeath
xSerious deterioration in the health of the subject that resulted in any of the following: 
xLife-threatening illness or injury 
xPermanent or persistent impairment of a body structure or a body function 
xHospitalization or prolongation of patient hospitalization 
xMedical or surgical intervention to prev ent life-threatening illness or injury or 
permanent impairment to a body structure or a body function. 
CR-6477, v 2.0  
Page 50 of 169JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
xChronic disease 
xFoetal distress, foetal death or a congenital physical or mental impairment of birth 
defect.
Diagnoses and conditions that are considered Oc ular Serious Adverse Events include, but not 
limited to:
xMicrobial Keratitis (MK)
xIritis (including cells in the anterior chamber)
xPermanent decrease in best spectacle corrected visual acuity equivalent to 2 acuity lines 
or greater
xCentral Corneal Opacity
xCentral Corneal Neovascularization
xUveitis
xEndophthalmitis 
xHypopyon 
xHyphemia 
xPenetration of Bo wman’s Membrane 
xPersistent Epithelial Defect
xLimbal cell Damage leading to Conjunctivalization
Significant Adverse Events  – are defined as events that are symptomatic and warrant 
discontinuation (temporary or perman ent) of the contact lens wear 
Diagnoses and conditions that are considered Oc ular Significant Adverse Events include, but 
not limited to the following:
xContact Lens Induced Pe ripheral Ulcer (CLPU) 
xSignificant Infiltrative Events (SIE)
xSuperior Epithelial Ar cuate Lesions (SEALs)
xAny Temporary Loss of > 2 Lines of BSCVA
xOther grade 3 or higher corneal findi ngs, such as abrasions or edema 
xNon-contact lens related corneal events - e.g. Epidemic Kera toconjunctivitis (EKC) 
xAsymptomatic Corneal Scar
xAny corneal event which necessitates te mporary lens discontinuation > 2 weeks
Non-Significant Adverse Events  – are defined as those events that are usually asymptomatic 
and usually do not warrant discon tinuation of contact lens wear but may cause a reduction in 
wear time.  However, the Investigator may choos e to prescribe treatment  as a precautionary 
measure.   
Diagnoses and conditions that are considered Ocular Non-Significant Adverse Events include, 
but not limited to the following:
xNon-significant Infiltrative Event (NSIE)
xContact Lens Papillary Conjunctivitis (CLPC)
xSuperficial Punctate Keratitis (SPK)
CR-6477, v 2.0  
Page 51 of 169JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
xConjunctivitis: Bacterial, Viral, Allergic
xBlepharitis
xMeibomianitis
xContact Dermatitis
xLocalized Allergic Reactions
xAny corneal event not explicitly defined as serious or significant adverse event, which 
necessitates temporary lens discontinuation < 2 weeks 
Adverse Device Effect (ADE) – An ADE is an “adverse event related to the use of an 
investigational medical device.” 
NOTE 1: This definition includes adverse events resulting from insufficient or 
inadequate instructions for use, deployment, implantation, installati on, or operation, or 
any malfunction of the inve stigational medical device. 
NOTE 2: This definition includes any event resulting from use error or from intentional 
misuse of the investigational medical device.
Unanticipated Adverse Device Effect (UADE) – A UADE is any serious adverse effect on 
health or safety or any life-threatening problem or death caused by, or associated with, the test 
article, if that effect, problem,  or death was not previously id entified in nature , severity, or 
degree of incidence in the investigational plan, Investigator’s Brochure or protocol, or any 
other unanticipated serious problem associated with the test article that relates to the rights, safety and welfare of subjects.
13.2. Assessing Adverse Events
In conjunction with the medical monitor, the Investigator will evaluate adverse events to ensure the events are categorized correctly. Elements of categorization will include: 
xSeriousness/Classifications (s ee definition in section 13.1). 
xCausality or Rela tedness – i.e. the relationship between  the test article , study treatment 
or study procedures and the adverse even t (not related, unlikely related, possibly 
related, or related - see definition in section 13.2.1). 
xAdverse Event Severity – Adverse event severity is used to assess the degree of intensity of the adverse event (mild, m oderate, or severe - see definition in 
section 13.2.2). 
xOutcome – not recovered or not resolved , recovering or resolving, recovered or 
resolved with sequelae, recovered or resolved, death related to adverse event, orunknown. 
xActions Taken – none, temporar ily discontinued, permanently  discontinued, or other. 
13.2.1. Causality Assessment
Causality Assessment – A determination of the relationship between an adverse event and the 
test article. The test article relationship for each adverse event should be determined by the 
investigator using these explanations: 
xNot Related- An adverse event that is not re lated to the use of the test article, study 
treatment or study procedures. 
CR-6477, v 2.0  
Page 52 of 169JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
xUnlikely Related – An adverse event for which an alternative explanation is more 
likely, e.g. concomitant treatme nt, concomitant disease(s), or the relationship of time 
suggests that a causal relationship is not likely. 
xPossibly Related – An adverse event that might be due to the use of the test article, or 
to the study treatment or study procedures. An alternative explanation, e.g. concomitant 
treatment, concomitant disease(s), is inconclusive. The relationship in time is reasonable. Therefore, the causal relationship cannot be excluded. 
xRelated – An adverse event that is listed as a possible adverse effect (device) or adverse reaction (drug) and cannot be reasonably e xplained by an alternative explanation, e.g. 
concomitant treatment of concomitant disease(s). The relationship in time is very suggestive, e.g. it is confirmed by de-challenge and re-challenge. 
13.2.2. Severity Assessment
Severity Assessment – A qualitative assessment of the degree of intensity of an adverse event 
as determined by the Investigator or reported to him/her by the subject. The assessment of 
severity is made irrespective of  test article, study tr eatment or study procedure relationship or 
seriousness of the event and should be eval uated according to the following scale: 
xMild – Event is noticeable to the subject but is easily tolerated and does not interfere with the subject’s daily activities.
xModerate – Event is bothersome, possibl e requiring additiona l therapy, and may 
interfere with the subject’s daily activities.
xSevere – Event is intolerable, necessitates additional ther apy or alterati on of therapy 
and interferes with the subject’s daily activities. 
13.3. Documentation and Follow-Up of Adverse Events
The recording and documenting of adverse even ts (ocular and non-ocular) begin when the 
subjects are exposed to the test article, study tr eatment or study procedure.  Adverse events 
reported before the use of test  article, start of study treatme nt, or study procedures will be
recorded as medical history. However, if the c ondition deteriorates at any time during the study 
it will be recorded and reported as an AE. Untoward medical events reported after the subject’s exit from the study will be recorded as adverse ev ents at the discretion of the Investigator. 
Upon finding an adverse event, the Principal In vestigator will document the condition in the 
subject record and in the eCRFs and complete the Adverse Event eCRF.  
Complete descriptions of all adverse events must be available in the subject record. All 
Adverse Events including local and systemic re actions not meeting the criteria for “serious 
adverse events” shall be captured on the appropriate case report form or electronic data system. All adverse events occurring while the subject  is enrolled in the study must be documented 
appropriately regardle ss of relationship.   
It is the Investigator’s responsibility to maintain documentation of each reported adverse event. All adverse events will be followed in accordance with applicable licensing requirements. Such 
documentation will include the following: 
xAdverse event (diagnosis not symptom). 
CR-6477, v 2.0  
Page 53 of 169JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
xDrawings or photographs (where appropri ate) that detail the finding (e.g., size, 
location, and depth, etc.). 
xDate the clinical site was notified.
xDate and time of onset.
xDate and time of resolution.
xAdverse event classification, se verity, and relationship to te st articles, as applicable. 
xTreatment regimen instituted (where appropriate), including concomitant medications 
prescribed, in accordance with applicable licensing requirements. 
xAny referral to another hea lth care provider if needed. 
xOutcome, ocular damage (if any). 
xLikely etiology. 
xBest corrected visual acuity at the discovery of the ev ent and upon conclusion of the
event, if the AE is related to the visual system.
Upon discovery of an AE that is deemed ‘possibly related’ or ‘related’ to the test article or 
study procedures (whether related to the visu al system or not), an AE review form 
must be completed. Additional dated and initialed entries should be made at follow-up 
evaluations. Separate forms must be completed for each eye if the AE is bilateral. 
In addition, if an infiltrate(s) is present, he/she will complete the Corneal Infiltrate Assessment 
eCRF. Where necessary, a culture of the corneal lesion will be collected to determine if the infection is microbial in nature. If cultures are collected, the date of culture collection and laboratory utilized will be recorded.  
Changes in the severity of an AE shall be documented to allow an assessment of the duration 
of the event at each level of intensity to be performed. Adverse events characterized as 
intermittent require documentation of the onset and duration of each episode. Changes in the assessment of relationship to the Test Article shall also be clearly documented.
Subjects who present with an adverse event sh all be followed by the Investigator, within 
licensure, until all signs and symptoms have retu rned to pre-treatment status, stabilized, or 
been satisfactorily resolved. If further treatme nt beyond licensure is required, the patient will 
be referred to the appropriate health care provider. The Investigator will use his/her clinical judgment as to whether a subject reporting with an adverse event will continue in the study. If a subject is discontinued from the study, it will be  the responsibility of the Investigator to 
record the reason for discontinuation. The Inves tigator will also document the adverse event 
appropriately and complete the Adverse Event eCRF. Any subjects with ongoing adverse events related to the test artic le, study treatment or study procedur es, as of the final study visit 
date, should be followed to resolu tion of the adverse event or un til referral to an appropriate 
health care provider, as recommended by the Investigator. Non-ocular adverse events that are not related to the test artic le, study treatment, or study proc edures may be recorded as 
“ongoing” without further follow-up. 
CR-6477, v 2.0  
Page 54 of 169JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
13.4. Reporting Adverse Events 
The Investigator will notify the Sponsor of an adverse event by e-mail, facsimile, or telephone 
as soon as possible and no later than 24 hours from discovery for an y serious /significant 
adverse events, and 2 days from discovery for any non-significant adverse event. In addition, 
a written report will be submitted by the Principal Investigator to the IEC/IRB according to their requirements (section 13.4.2). The report w ill comment whether the adverse event was 
considered to be related to the test article, study tr eatment or study procedures. 
13.4.1. Reporting Adverse Events to Sponsor 
Serious/Significant Adverse Events
The Investigator will inform the sponsor of a ll serious/significant adve rse events occurring 
during the study period as soon as possible by e- mail or telephone, but no  later than 24 hours 
following discovery of the event. The Invest igator is obligated to pursue and obtain 
information requested by the Sponsor in addition to that information reported on the eCRF. All 
subjects experiencing a serious/si gnificant adverse event must be  followed up and all outcomes 
must be reported. 
When medically necessary, the Investigator ma y break the randomizati on code to determine 
the identity of the treatment that the subject received. The Sponsor and study monitor should 
be notified prior to unmas king the test articles. 
In the event of a serious/significant adverse event, the Investigator must: 
xNotify the Sponsor immediately.
xObtain and maintain in the subject’s records all pertinent medical information and medical judgment for colleague s who assisted in the treatment and follow-up of the 
subject.
xProvide the Sponsor with a complete case history which includes a statement as to 
whether the event was or was not related to the use of the test article. 
xNotify the IEC/IRB as required by the IE C/IRB reporting procedure according to 
national regulations. 
Unanticipated (Serious) Adverse Device Effect (UADE)In the event of an Unanticipated (Serious) Adverse Device Effect (UADE), the Investigator will submit a report of the UADE to the Sponsor and IEC/IRB as soon as possible, but no later
than 24 hours after the Investigator first learns of  the effect. This report is in addition to the 
immediate notificati on mentioned above.
The Sponsor must conduct an evaluation of th e UADE and must report the results of the 
evaluation to FDA, the IEC/IRB and participati ng Investigators within 10 working days after 
the Sponsor first receives notification of the effect. 
Non-Serious Adverse EventsAll non-serious adverse events, including non-seri ous adverse device effects, will be reported 
to the sponsor by the Investigator no later than 2 days from discovery. 
CR-6477, v 2.0  
Page 55 of 169JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
13.4.2. Reporting Adverse Events to the Resp onsible IEC/IRB and Health Authorities
Adverse events that meet the IEC/IRB requirements for reporting must be reported within the 
IEC/IRB’s written guidelines. Each clinical site will refer to and follow any guidelines set forth by their Approving IEC/IRB. Each clinical site wi ll refer to and follow any guidelines set forth 
by their local governing Health Authorities. 
The Sponsor will report applicable Adverse Events  to the local health authorities according to 
the written guidelines, including reporting timelines.  
13.5. Event of Special Interest
None 
13.6. Reporting of Pregnancy 
Subjects reporting pregnancy (by self-report) during the study will be discontinued after the 
event is recorded as an Adverse Event. Once  discontinued, pregnant participants and their 
fetuses will not be monitored for study related purposes. Pregnant participants are not 
discontinued from contact lens or  solution related studies for safety concerns, but due to 
general concerns relating to pre gnancy and contact lens use. Sp ecifically, pregnant women are 
discontinued due to fluctuations in refractive error and/or visual  acuity that occur secondary to 
systemic hormonal changes, and not due to unforeseen health risks to the mother or fetus. 
14. STATISTICAL METHODS
14.1. General Considerations
Statistical Analysis will be undertaken by the sponsor or under the authority of the sponsor. A 
general description of th e statistical methods to be implemented in this clinical trial is outlined
below. More details will be included in the stand-alone Statistical Analysis Plan (SAP). TheSAP will be developed and finalized prior to database lock. 
All data summaries and statistical analyses will be performed using the Statistical Analysis 
System (SAS) software Version 9.4 or higher (SAS Institute, Cary, NC).
14  Throughout the 
analysis of data, the results for each subject/eye will be used when available for summarization and statistical analysis. Unscheduled visits will be summarized separately and will be excluded from the statistical analysis.
Summary tables (Descriptive statistics and/or frequency tables) will be provided for all 
baseline variables, efficacy variables and safety  variables as appropriate. Continuous variables 
will be summarized with descriptive statistics (n, mean, standard deviation [SD], median, minimum and maximum). Frequency count and percentage of subj ects or eyes within each 
category will be provided for categorical data.
Summaries will be presented by se parately for each time point (Baseline, fitting, 3-Day follow-
up, 1-week follow-up) and will be performed separately by completion status (Safety 
Population, Per-Protocol Population or In tent-to-treat, when appropriate).   
CR-6477, v 2.0  
Page 56 of 169JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
=5%). All co-primary safety and co-primary efficacy hypotheses must be met to test any 
secondary hypotheses. 
Secondary hypotheses  (except for lens fit success) will be tested with using an overall two-
sided family-wise type I error rate of 5% (1% individually). Lens fit success will be tested 
using a 99% credible interval. 
14.5. Primary Analysis  
Primary Safety Analyses:
All primary safety analysis will be  conducted on the safety population.  
Grade 3 or Higher SLF Grade 3 of Higher SLFs will be analyzed using a Bayesian beta-binomial model with correlated 
binary data
17.
The Model:
Let ܻଵ and ܻଶdenote the binary outcomes of lens fit acce ptance (Yes/No) in left and right eyes, 
respectively, across dispensing and follow-up visits  when wearing the Test lens. Considering 
the correlation,  ߩ ,between ܻଵ and ܻଶ, the distribution of the sum ܻ = ܻଵ + ܻଶ is obtained by 
the mixture of two variables. One of them follow a binomial distribution ݊݅ܤ(2,݌)with mixing 
probability (1െ ߩ)and the other one follows a m odified Bernoulli distribution, ݊ݎ݁ܤܯ( ݌),
taking value 0 and 2 rather than conven tional 0 and 1, with mixing probability ߩ:
ܲ(ܻ = ݕ| ݌,ߩ( = ) 1െ ߩ)݊݅ܤ(2,݌)ܫ஺ଵ +  ݊ݎ݁ܤܯߩ( ݌)ܫ஺ଶ ,
where ܫ஺ଵ = { 0 ,1 ,2 } ,ܫ஺ଶ= { 0 ,2 }  and ݌is the probability of success (i.e., acceptable lens 
fitting).  
To overcome the complexity of the mixture likelihood a latent variable ܼ௜, i = 1, 2 is introduced 
in the model to indicate in which co mponent of the model the observation ݕ௜, i=1, 2, belongs 
to, that is,
ܼ௜=൜1, if the observation belong to the MBern(p),
0, if the observation belong to the Bin(2, p)  
The joint distribution of the augmented data (ܻ௜,ܼ௜),݅=1 ,2 , is given by 
P(Y=y୧,Z =z୧| p,ɏ)
=  ɏ୸౟p୷౟୸౟/ଶ(1െp)(ଶି୷౟)୸౟/ଶ(1െɏ)ଵି୸౟൬2
y୧൰p୷౟(ଵି୸౟)(1െp)(ଶି୷౟)(ଵି୸౟)
The probability p links to the regression variab les through a logit transformation as follow: 
logit (p)=  Ⱦ଴+ Ⱦଵlens
It is assumed that Ⱦ଴,Ⱦଵ and ߩto be independent with a non- informative prior N(0, 1000) for 
Ⱦ଴ andȾଵ,and beta(0.5, 0.5) for ߩ .The Metropolis sampler algorithm as implemented in the 
SAS/STAT MCMC Procedure14will be used to estimate the posterior distributions of the 
CR-6477, v 2.0  
Page 61 of 169JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
parameters ( Ⱦ଴,Ⱦଵ,ߩ .)Inferences will be made based on a posterior credible interval for the 
relevant parameters.  
Bayesian Estimation and Statistical Evaluation of Hypothesis:
Superiority of the Test lens relative to the pr e-defined threshold with respect to Grade 3 or 
higher will be evaluated using Bayesian statistics. 
Primary Safety Hypothesis 1:  
The null and alternative hypotheses for evaluating s uperiority of the Test lens relative to 5% 
are as follows: 
ܪ଴: ݌୘൒0.05
ܪ஺: ݌୘<0 . 0 5 ,
where ݌୘is the probability of a Grade 3 or higher SLF across all study visits for Test lens. 
Based on Bayesian poste rior probability distribution of the proportion ݌், superiority is 
interpreted as 95% probability of Test being statistically lower than the threshold of 5% (i.e., 
݌୘<0 . 0 5 ). If the upper bound of the 95% central posterior credible interval is below 0.05, it 
can be concluded that there is 95% probability that the Test lens is superior to 5% (statistically 
less than) based on the observed sample.  
In the case of zero clinically significant SLF, a Bayesian hierarchical model accounting for 
zero event problem will be considered18.  
Unacceptable Lens Fitting Lens fit acceptance will be analyzed using a Bayesian beta-binomial model with correlated binary data
17.
Bayesian Estimation and Statistical Evaluation of Hypothesis:Superiority of the Test lens relative to the pre-defined threshold with respect to unacceptable lens fitting will be evaluated using Bayesian statistics. 
Primary Safety Hypothesis 2:  
The null and alternative hypotheses for evaluating s uperiority of the Test lens relative to 5% 
are as follows: 
ܪ
଴: ݌୘൒0.05
ܪ஺: ݌୘<0 . 0 5 ,
where ݌୘is the probability of event (i.e., probability  of unacceptable lens fitting while wearing 
the test lens). Based on Bayesian posteri or probability distribution of the proportion ݌்,
superiority is interpreted as 95% probability of the Test lens being statistically lower than the 
pre-defined threshold of 5% (i.e., ݌୘<0 . 0 5 ) with respect to unacceptable lens fitting rate. If 
the upper bound of the 95% central posterior cr edible interval is below 0.05, it can be 
CR-6477, v 2.0  
Page 62 of 169JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
concluded that there is 95% probability that the Test lens is superior to the 5% threshold 
(statistically less) based on the observed sample.  
In the case of all eyes have an acceptable lens fit (i.e., zero unacceptable lens fit), a Bayesian 
hierarchical model accounting for zero event problem will be considered. Details of this model 
will be provided in the stand-along SAP18.   
Primary Efficacy Analyses: All primary efficacy analyses will be c onducted on the intent-to-treat population.  
Threshold utilized in hypothesis testing related to CLUE vision scores were based on a meta-analysis of CLUE vision scores for the Market leader for multifocal lenses, Air Optix
21.   
CLUE Vision Scores Mean population estimates and two-sided 95% confidence intervals will be computed 
separately for each stratum ( hyperopes and myopes) using a bootstrap methodology. At least 
a total of 20000 bootstrap iterations will be used following the suggestions of Samuelson and 
Petrick
19. A minimum threshold of 4000 bootstra p iterations was recommended for an 
alpha=0.05, however, since each test will be  performed using alpha=0.01, it is more 
appropriate to increase number of bootstrap ite rations. The assessment of the impact of the 
autocorrelation for between subjects repeated measurements, is defined by the difference between the observed statistic compared to the bootstrapped population mean (bias= observed minus bootstrapped population mean). This appro ach was recommended for all estimations of 
statistical inference since this approach accommodates correlated data . The bootstrap analysis 
that will be performed followed a procedure as  discussed by Davison, AC and Hinkley, DV
20. 
Primary Efficacy Hypothesis 1:  The null and alternative hypothesis to test for s uperiority of Myopes relative to the threshold 
41 CLUE points are as follows: 
ܪ
௢:ߤ்௘௦௧൑41
ܪ஺:ߤ்௘௦௧ >4 1
Where ߤ்௘௦௧, represents the population mean for Myopes  at the 1-week follow-up with respect 
to CLUE vision scores. Superiority will be declared if the lower limit of the 95% CI is above 41.
Primary Efficacy Hypothesis 2: 
The null and alternative hypothesis to  test for superiority of Hyperopes relative to the threshold 
36 CLUE points are as follows: 
ܪ
௢:ߤ்௘௦௧൑36
ܪ஺:ߤ்௘௦௧ >3 6
CR-6477, v 2.0  
Page 63 of 169JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
Where ߤ்௘௦௧, represents the population mean for H yperopes at the 1-week follow-up with 
respect to CLUE vision scores. Superiority will be declared if the lower limit of the 95% CI is
above 36.   
Visual Performance (logMAR) 
Binocular HLHC visual performance will utilize the same bootstrapping methodology as 
described above for CLUE vision. However, with respect to VP, mean population estimates and two-sided 95% confidence intervals will be computed separately for each distance (distance 4m, intermediate 64cm and near 40 cm) but will combine the hyperopic and myopic 
populations. At least a total of 20000 bootstrap ite rations will be used following the suggestions 
of Samuelson and Petrick
19. A minimum threshold of 4000 bootstrap iterations was 
recommended for an alpha=0.05, however, since e ach test will be performed using alpha=0.01, 
it is more appropriate to increase number of boot strap iterations. The assessment of the impact 
of the autocorrelation for between subjects repeated measurements, is defined by the differencebetween the observed statistic compared to the bootstrapped population mean (bias= observed minus bootstrapped population mean). This appro ach was recommended for all estimations of 
statistical inference since this approach accommodates correlated data . The bootstrap analysis 
that will be performed followed a procedure as  discussed by Davison, AC and Hinkley, DV
20.  
Primary Efficacy Hypothesis 3:The null and alternative hypothesis for binocular distance HLHC visual performance to test 
for superiority of Aurora relative to th e threshold 0.0 logMAR are as follows: 
ܪ
௢:ߤ்௘௦௧൒0 logMAR 
ܪ஺:ߤ்௘௦௧ <0 logMAR 
Where ߤ்௘௦௧, represents the population mean for Auro ra at the 1-week follow-up with respect 
to distance HLHC visual performance. Superiority will be declared if the upper limit of the 95% CI is below 0.0.   
Primary Efficacy Hypotheses 4 and 5:
The null and alternative hypothesis for binocul ar intermediate and near HLHC visual 
performance to test for superiority of Aurora  relative to the threshold 0.17 logMAR are as 
follows: 
ܪ
௢:ߤ்௘௦௧൒0.17 logMAR 
ܪ஺:ߤ்௘௦௧ <0 . 1 7  logMAR 
Where ߤ்௘௦௧, represents the population mean for Auro ra at the 1-week follow-up with respect 
to HLHC visual performance. Superiority will be declared if the upper limit of the 95% CI 
for either intermediate or near is below 0.17.   
CR-6477, v 2.0  
Page 64 of 169JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
14.6. Secondary Analysis  
All secondary analyses will be conduc ted on the Intent-to-Treat population.  
Threshold utilized in hypothesis testing relate d to CLUE vision, comfort and handling scores 
were based on a meta-analysis of CLUE vision, comfort and handling scores for the Market 
leader for multifocal lenses, Air Optix21.   
CLUE Vision
Secondary hypotheses 1 and 2 will be tested using the same estimates and 95% CIs from the 
analysis as described for CLUE Vision in section 14.5. The hypotheses te sts will be performed 
separately for Hyperopes and Myopes using 2-sided 95% confid ence intervals constructed for 
the population mean at the 1-week follow-up evaluation.
Secondary Hypothesis 1:  
The null and alternative hypothesis to test for superiority of  Myopes relative to the threshold 
46 CLUE points are as follows: 
ܪ௢:ߤ்௘௦௧൑46
ܪ஺:ߤ்௘௦௧ >4 6
Where ߤ்௘௦௧, represents the population mean for Auro ra Hyperopes at the 1-week follow-up 
with respect to CLUE vision scores. Superiority will be declared if the lower limit of the 95% CI is above 46.   
Secondary Hypothesis 2:  
The null and alternative hypothesis to  test for superiority of Hype ropes relative to the threshold 
41 CLUE points are as follows: 
ܪ
௢:ߤ்௘௦௧൑41
ܪ஺:ߤ்௘௦௧ >4 1
Where ߤ்௘௦௧, represents the population mean for Auro ra Hyperopes at the 1-week follow-up 
with respect to CLUE vision scores. Superiority will be declared if the lower limit of the 95% CI is above 41.   
CLUE Comfort and Handling 
Mean population estimates and 95% CIs for CLUE  comfort and handli ng will be calculated 
separately using bootstrapping techniques. For both  comfort and handling scores, a minimum 
of 20000 bootstrap iterations will be used foll owing the suggestions of Samuelson and 
Petrick
19. A minimum threshold of 4000 bootstra p iterations was recommended for an 
alpha=0.05, however, since each test will be  performed using alpha=0.01, it is more 
appropriate to increase number of bootstrap ite rations. The assessment of the impact of the 
autocorrelation for between subjects repeated measurements, is defined by the difference between the observed statistic compared to the bootstrapped population mean (bias= observed 
CR-6477, v 2.0  
Page 65 of 169JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
minus bootstrapped population mean). This appro ach was recommended for all estimations of 
statistical inference since this approach accommodates correlated data . The bootstrap analysis 
that will be performed followed a procedure as  discussed by Davison, AC and Hinkley, DV20.
Secondary hypotheses 3 and 4 w ill be tested using the data  from hyperopes and myopes 
combined since there is not a significant difference in performance between these two 
populations. The hypotheses tests will be performed separately for Comfort and Handling 
using 2-sided 95% confidence intervals constr ucted for the population means at the 1-week 
follow-up evaluation. 
Secondary Hypothesis 3:  
The null and alternative hypothesis to  test for superiority for Comf ort of the Test lens relative 
to the threshold 52 CLUE points are as follows: 
ܪ௢:ߤ்௘௦௧൑52
ܪ஺:ߤ்௘௦௧ >5 2
Where ߤ்௘௦௧, represents the population mean for the Te st lens at the 1-week follow-up with 
respect to CLUE comfort scores. Superiority will be declared if the lower limit of the 95% CI is above 52.   
Secondary Hypothesis 4:  
The null and alternative hypothesis to test for superiority for Handling of  Test lens relative to 
the threshold 53 CLUE points are as follows: 
ܪ
௢:ߤ்௘௦௧൑53
ܪ஺:ߤ்௘௦௧ >5 3
Where ߤ்௘௦௧, represents the population mean for the Te st lens at the 1-week follow-up with 
respect to CLUE Handling scores. Superiority will be declared if the lower limit of the 95% 
CI is above 53.   
Number of Lenses Required to Achieve Optimization 
Number of lenses required to achieve lens optimization will be analyzed using a Bayesian beta-binomial model with correlated binary data
17.  
Bayesian Estimation and Statistical Evaluation of Hypothesis:Superiority of the Test lens relative to the pre-defined threshold with respect to unacceptable lens fitting will be evaluated using Bayesian statistics. The null and alternative hypotheses for evaluating superiority of the Test lens relative to 5% are as follows: 
ܪ
଴: ݌୘൑0.90
ܪ஺: ݌୘>0 . 9 0 ,
where ݌୘is the probability of event (i.e., proporti on of subjects to achieve optimization in 4 
lenses or less while wearing the test lens). Based on Bayesian posterior probability distribution 
of the proportion ݌், superiority is interpreted as 95% probability of the Test lens being 
statistically greater than the pr e-defined threshold of 90% (i.e., ݌୘>0 . 9 0 ) with respect to 
CR-6477, v 2.0  
Page 66 of 169JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
14.8. Interim Analysis  
There will not be an interim analysis performed on this study.  
14.9. Procedure for Handling Mi ssing Data and Drop-Outs
Missing or spurious values will not be imputed. The count of missing values will be included 
in the summary tables and listings. 
Subject dropout is expected to be one of the main reasons of missing data in this clinical trial. 
Past clinical trials don’t provide the evidence that subject dropout is systematic or not-at-
random. To evaluate the impact of missing data , sensitivity analysis will be conducted using 
multiple imputation methods if the proportion of subject dropout is greater than the 10%. The 
SAS/STAT procedures PROC MI and PROC MI ANALYZE will be utilized with a parametric 
regression method used to ma ke at least 50 imputations.
14.10.Procedure for Reporting Devi ations from Statistical Plan
The analysis will be conducted according to that specified in above sections. There are no known reasons for which it is planned to deviate fr om these analysis methods. If for any reason 
a change is made, the change will be documented in the study re port along with a justification 
for the change.
15. DATA HANDLING AND RECORD KEEPING/ARCHIVING
15.1. Electronic Case Report Form/Data Collection
The data for this study will be captured on electronic case report forms (eCRFs) using the 
BioClinica EDC system. An authorized data or iginator will enter study data into the eCRFs 
using the EDC system. Data collected on equipment that is not captured in EDC will be formatted to the specification of the JJVC databa se manager and sent to JJVC for analysis.  
External data sources for this study include: Not Applicable
The clinical data will be recorded on dedicated eCRFs specifically designed to match the study 
procedures for each visit. Only specifically delegated staff can enter data on a CRF.  Once completed, the eCRFs will be reviewed for accuracy and completeness and signed by the Investigator. The sponsor or sponsor’s representa tives will be authorized to gain access to the 
subject recordation for the purposes of  monitoring and auditing the study.  
Edit checks, electronic queries, and audit trails are built into the system to ensure accurate and complete data collection. Data w ill be transmitted from the clinical site to a secure central 
database as forms are completed or updated, ensuring information accuracy, security, and 
confidentiality. After the final database lock, the Investigator will be provided with Individual Patient Profiles (IPP) including the full audit trail on electronic media in PDF format for all of the study data. The IPP must be retained in the st udy files as a certified copy of the source data 
for the study.  
CR-6477, v 2.0  
Page 68 of 169JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
The content and structure of the eCRFs are compliant with ISO14155:2020.Error! Reference source 
not found.
15.2. Subject Record
At a minimum, subject record should be available for the following:  
xsubject identification
xeligibility
xstudy identification
xstudy discussion 
xprovision of and date of informed consent 
xvisit dates
xresults of safety and efficacy para meters as required by the protocol 
xa record of all adverse events
xfollow-up of adverse events 
xmedical history and concomitant medication
xtest article receipt/dispensing/return records
xdate of study completion 
xreason for early discontinuation of test article or withdrawal from the study, if 
applicable
The subject record is the eCRF or an external record. The author of an entry in the subject 
record must be identifiable. The first point of  entry is considered to be the source record.
Adverse event notes must be reviewed and initialed by the Investigator. 
15.3. Trial Registration on ClinicalTrials.gov  
This study will be registered on ClinicalTrials .gov based on the following: This study is not an 
early feasibility study.  
16. DATA MANAGEMENT
16.1. Access to Source Data/Document
The Investigator/Institution will permit trial-rela ted monitoring, audits, IEC/IRB review and 
regulatory inspection(s) by providing direct access to source data/documents. Should the 
clinical site be contacted for an audit by an IEC/IRB or regulatory authority, JJVC must be 
contacted and notified in  writing within 24 hours. 
16.2. Confidentiality of Information 
Information concerning the inves tigational product and pa tent application pro cesses, scientific 
data or other pertinent inform ation is confidential and rema ins the property of JJVC. The 
Investigator may use this information for the purposes of the study only. It is understood by 
the Investigator that JJVC will use information developed in this clinical study in connection 
CR-6477, v 2.0  
Page 69 of 169JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
with the development of the investigational product a nd therefore may disclose it as required 
to other clinical investigators and to regulatory agencies. In order to allow the use of the 
information derived from this clinical study, the Investigator understands  that he/she has an 
obligation to provide complete test results and all data developed during this study to the 
Sponsor.
16.3. Data Quality Assurance 
Steps will be taken to ensure the accuracy and reliability of data, include the selection of 
qualified investigators and appropriate clinical sites and revi ew of protocol procedures with 
the Principal Investigator. The Principal Investigator, in turn, must ensure that all Sub-Investigators and clinical site  personnel are familiar with the pr otocol and all study-specific 
procedures and have appropriate  knowledge of the study article. 
Training on case report form completion will be pr ovided to clinical site personnel before the 
start of the study. The Sponsor will review case  report forms for accuracy and completeness 
remotely during the conduct of the study, during monitoring visits, and after transmission to 
data management. Any data discrepancies will be resolved with the Investigator or designee, as appropriate.
Quality Assurance representatives from JJVC may visit clinical sites to review data produced 
during the study and to access compliance with applicable regulations pertaining to the conduct of clinical trials. The clinical sites will provide direct access to study-related source data/documents and reports for the purpose of monitoring and auditing by JJVC and for inspection by local and regulatory authorities. 
16.4. Data Monitoring Committee (DMC)
Not Applicable.  
17. CLINICAL MONITORING
The study monitors will maintain close contact  with the Principal Investigator and the 
Investigator’s designated clinical site personnel. The monitor’s responsibilities will include:
xEnsuring that the investigation is being conducted according to the protocol, any 
subsequent versions, and regulat ory requirements are maintained. 
xEnsuring the rights and wellbei ng of subjects are protected. 
xEnsuring adequate resources, including fac ilities, laboratories, equipment, and 
qualified clinical site personnel.
xEnsuring that protocol deviations are doc umented with corrective action plans, as 
applicable. 
xEnsuring that the clinical site has sufficient test article and supplies. 
xClarifying questions regarding the study. 
xResolving study issues or problems that may arise. 
xReviewing of study records and source documentation verification in accordance with 
the monitoring plan. 
CR-6477, v 2.0  
Page 70 of 169JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
18. ETHICAL AND REGULATORY ASPECTS
18.1. Study-Specific Desi gn Considerations
Potential subjects will be fully informed of the risks and requirements of the study and, during 
the study, subjects will be given any new informati on that may affect their decision to continue 
participation. Subjects will be told that their consent to participate in the study is voluntary and 
may be withdrawn at any time with  no reason given and without pena lty or loss of benefits to 
which they would otherwise be entitled. Subjects will only be enrolled if the subject is fully 
able to understand the risks, be nefits, and potential adverse events of the study and provide
their consent voluntarily. 
18.2. Investigator Responsibility 
The Principal Investigator is responsible for en suring that the clinical study is performed in 
accordance with the signed agreement, the investigational plan, section 4 of the ICH E6(R2)guidelines on Good Clinical Practice (GCP),
Error! Reference source not found.and applicable regulatory 
requirements. GCP is an international ethical and scientific quality standard for designing, conducting, recording, and reporting studies that involve the participation of human subjects. Compliance with this standard provides public a ssurance that the rights, safety, and well-being 
of study subjects are protected, cons istent with the principles of the Declaration of Helsinki 
64
thWMA General Assembly 2013Error! Reference source not found.and that the clinical study data 
are credible. The Investigator must maintain cl inical study files in accordance with section 8 
of the ICH E6(R2) guidelines on Good Clinical Practice (GCP),Error! Reference source not found.and 
applicable regulatory requirements.
18.3. Independent Ethics Comm ittee or Institutional Review Board (IEC/IRB)
Before the start of the study, the Investigator (or Sponsor when applicable) will provide the IEC/IRB with current and complete copies of  the following documents (where applicable): 
xFinal protocol. 
xSponsor-approved informed consent form (a nd any other written materials to be 
provided to the subjects) 
xInvestigator’s Brochure (o r equivalent information). 
xSponsor-approved subject r ecruitment materials. 
xInformation on compensation for study-relate d injuries or payment to subjects for 
participation in the study.
xInvestigator’s curriculum vitae, clinical lic enses, or equivalent information (unless not 
required, as documented by IEC/IRB). 
xInformation regarding funding, name of the Sponsor, institutional affiliations, other potential conflicts of interest, and incentives for subjects. 
xAny other documents that the IEC/IRB requests to fulfill its obligation. 
This study will be undertaken only after IEC/IRB has given full approval of  the final protocol,
the informed consent form, applicable recruiting materials, and subject compensation programs, and the Sponsor has received a copy of  this approval. This approval letter must be 
dated and must clearly identify the documents being approved. 
CR-6477, v 2.0  
Page 71 of 169JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
During the study, the Investigator (or Sponsor  when applicable) will send the following 
documents to the IEC/IRB for their review and approval, where appropriate: 
xProtocol revisions 
xRevision(s) to informed consent form and any other written materials to be provided to 
subjects
xIf applicable, new or revised subject recr uitment materials approved by the Sponsor 
xRevisions to compensation for study-relate d injuries or payment to subjects for 
participation in the study 
xInvestigator’s Brochure revisions  
xSummaries of the status of the study (at leas t annually or at intervals stipulated in 
guidelines of the IEC/IRB) 
xReports of adverse events that are serious, unanticipated, and associated with the test articles, according to the IRB’s requirements 
xNew information that may adversely affect th e safety of the subjects or the conduct of 
the study 
xMajor protocol deviations as required by the IEC/IRB 
xReport of deaths of subjects under the Investigator's care 
xNotification if a new Investigator is res ponsible for the study at the clinical site
xAny other requirements of the IEC/IRB 
For protocol revisions that incr ease subject risk, the revisions and applicable informed consent 
form revisions must be submitted promptly to the IEC/IRB for review and approval before implementation of the change(s). 
At least once a year, the IEC/IRB will review an d reapprove this clinical study. This request 
should be documented in writing. At the end of the study, the Investigator (or S ponsor where required) will notify the IEC/IRB 
about the study completion. Documentation of this no tification must be retained at the clinical 
site and a copy provided to the CRO or Sponsor as applicable. 
18.4. Informed Consent
Each subject or their representative, must give written consent according to local requirements 
after the nature of the study has been fully explained. The consent form must be signed before performance of any study-related activity. The cons ent form that is used must be approved by 
both the Sponsor and by the reviewing IEC/IRB. Th e informed consent is in accordance with 
principles that originated in the Declaration of Helsinki,
Error! Reference source not found.Error! Reference 
source not found.current ICH GCPError! Reference source not found.and ISO 14155:2020Error! Reference source not 
found.guidelines, applicable regulatory requirements, and Sponsor Policy. 
Before entry into the study, the Investigator or an authorized member of the clinical site 
personnel must explain to potential subject the aims, methods, reasonably anticipated benefits, 
and potential hazards of the study, and any discom fort it may entail. Subjects will be informed 
CR-6477, v 2.0  
Page 72 of 169JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
that their participation is voluntary and that they may withdraw consent to participate at any 
time. 
18.5. Privacy of Personal Data 
The collection, processing and disclosure of pers onal data and medical information related to 
the Study Subject, and personal data  related to Principal Investig ator and any clinical site 
personnel (e.g., name, clinic addr ess and phone number, curriculum vitae) is subject to 
compliance with the Health Information Port ability and Accountability Act (HIPAA) and other 
applicable personal data protection and security  laws and regulations.15,16 Appropriate 
measures will be employed to safeguard these data, to maintain the confidentiality of the person’s related health and me dical information, to properly inform the concerned persons 
about the collection and processing of their pers onal data, to grant them reasonable access to 
their personal data and to preven t access by unauthorized persons. 
All information obtained during the course of the investigation will be regarded as confidential. 
All personal data gathered in this trial will be treated in strictest confidence by Investigators, monitors, Sponsor’s personnel and IEC/IRB. No data will be disclose d to any third party 
without the express permission of the subject  concerned, with the exception of Sponsor 
personnel (monitor, auditor), IEC/IRB and regulat ory organizations in the context of their 
investigation related ac tivities that, as part of the inves tigation will have access to the CRFs 
and subject records. 
The collection and processing of personal data from subjects enrolled in this study will be 
limited to those data that are necessary to investigate the efficacy, safety, quality, and utility of the investigational product( s) used in this study. 
These data must be collected and processed with  adequate precautions to ensure confidentiality 
and compliance with applicable data pr ivacy protection laws and regulations. 
The Sponsor ensures that the personal data will be: 
xprocessed fairly and lawfully. 
xcollected for specified, explicit, and legitimate purposes and not further processed in a way incompatible with these purposes. 
xadequate, relevant, and not excessive in relation to said purposes. 
xaccurate and, where necessary, kept current. 
Explicit consent for the processing of personal data will be obtained from the participating 
subject before collection of data . Such consent should also addres s the transfer of the data to 
other entities and to other countries. 
The subject has the right to request through the Investigator access to hi s personal data and the 
right to request rectification of any data that are not correct or complete. Reasonable steps 
should be taken to respond to such  a request, taking into considera tion the nature of the request, 
the conditions of the study, and the applicable laws and regulations. 
CR-6477, v 2.0  
Page 73 of 169JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
Appropriate technical and orga nizational measures to protec t the personal data against 
unauthorized disclosures or access, accidental or unlawful destruction, or accidental loss or 
alteration must be put in place. Sponsor pe rsonnel whose responsibilities require access to 
personal data agree to keep the id entity of study subjects confidential. 
19. STUDY RECORD RETENTION
In compliance with the ICH GCP guidelines, the Investigator/Institution will maintain all CRFs 
and all subject records that support the data co llected from each subject, as well as all study 
documents as specified in ICH GCP and all study documents as specified by the applicable regulatory requirement(s).
Error! Reference source not found.The Investigator/Institution will take 
measures to prevent accidental or pr emature destruction of these documents. 
Essential documents must be retained until at least two (2) years after the last approval of a marketing application in an ICH region and until there are no pending or contemplated marketing applications in an ICH region or until at least two (2) years have elapsed since the formal discontinuation of clin ical development of the i nvestigational product. These 
documents will be retained for a longer period if required by the applicable regulatory requirements or instructed by the Sponsor. It is the responsibility of the Sponsor to inform the Investigator/Institution as to when these documents no longer need to be retained. 
If the responsible Investigator retires, relocat es, or for other reasons withdraws from the 
responsibility of keeping the study records, custody must be transferred to a person who will accept the responsibility. The Sponsor must be no tified in writing of the name and address of 
the new custodian. Under no circumstance shall the Investigator relocate or dispose of any 
study documents before having obtaine d written approval from the Sponsor. 
If it becomes necessary for the Sponsor or the ap propriate regulatory auth ority to review any 
documentation relating to this study, the Investig ator must permit access to such reports.  
If the Investigator has a question regarding rete ntion of study records, he/she should contact 
JJVC.
20. FINANCIAL CONSIDERATIONS
Remuneration for study services and expenses will be set forth in de tail in the Clinical Research 
Agreement. The Research Agreement will be signed by the Principal Investigator and a JJVC 
management representativ e prior to study initiation.
JJVC reserves the right to withhold remuneration fo r costs associated with protocol violations 
such as:
xContinuing an ineligible subject in the study. 
xScheduling a study visit outside the subject’s acceptable visit range. 
JJVC reserves the right to withhold final rem uneration until all study related activ ities have 
been completed, such as:
CR-6477, v 2.0  
Page 74 of 169JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
xQuery resolution. 
xCase Report Form signature. 
xCompletion of any follow-up action items. 
21. PUBLICATION
There is no plan to publish the outcome of this investigation. 
22. REFERENCES
1. ISO 14155:2020: Clinical Investigation of  Medical Devices for Human Subjects — 
Good Clinical Practice. Available at https://www.iso.org/standard/45557.html 
2. International Conference on Harmonization Good Clinical Practice E6 (ICH-GCP). 
Available at http://www.ich.org/products /guidelines/efficacy/article/efficacy-
guidelines.html  
3. Declaration of Helsinki - Ethical principles for Medical Research Involving Human 
Subjects. Available at https://www.wma.ne t/policies-post/wma-dec laration-of-helsinki-
ethical-principles-for-medical -research-involvi ng-human-subjects/
4. United States (US) Code of Federa l Regulations (CFR). . Available at 
https://www.gpo.gov/fdsys/browse/collec tionCfr.action?collectionCode=CFR  
5. Karkkainen TR.  Investigator Brochure CR-6477  . 
6. Karkkainen TR.  Clinical Study Report  Evaluation of a 
Daily Disposable Multifocal Contact Lens with an UV Blocker Additive . June 25, 2019 
7. Thomas R. Karkkaine n.  Clinical Study Report 
Dispensing evaluation of daily disposable multifocal contact lenses in a population of 
hyperopic presbyopes . March 18, 2020 
8. Thomas R. Karkkaine n.  Clinical Study Report  Evaluation 
of a Daily Disposable Novel Multifocal Contact Lens in a Myopic Population . January 
06, 2021 
9. Karkkainen TR.  Clinical Study Report  Evaluation of a 
Daily Disposable Novel Multifocal Contact Lens in a Hyperopic Population . April 05, 
2021
10. Karkkainen TR.  Clinical Study Report  Evaluation of a 
Daily Disposable Novel Multifocal Contact Lens in a Myopic Population. May 21, 2021 
11. Karkkainen TR.  Clinical Study Protocol  Evaluation of 
Investigational Daily Disposable Multifocal Contact Lenses Produced with Different Manufacturing Processes . February 10, 2021 
12. Karkkainen TR.  Clinical Study Protocol  Evaluation of 
Daily Disposable Multifocal Contact Lenses Made With Two Diffe rent Manufacturing 
Processes . April 19, 2021 
CR-6477, v 2.0  
Page 75 of 169JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
13. Karkkainen TR.  Clinical Study Protocol  Evaluation of 
Investigational Daily Disposable Multifocal Contact Lenses Produced with Different 
Manufacturing Processes in Myopes . April 23, 2021 
14. SAS Institute Inc. 2016 SAS/STAT® 14.3 User’s Guide. Cary, NC: SAS Institute Inc.  
15. Health Information Portability and A ccountability Act (HIPAA). Available at 
https://www.hhs.gov/hipaa/for-professionals/privacy/index.html  
16. Regulation (EU) 2017/745 of the European Parliament and of th e Council of 5 April 
2017 on medical devices. Available at h ttp://data.europa.eu/e li/reg/2017/745/2017-05-05
17. Diniz CAR, Tutia MH, Leite JG. Bayesian analysis of a correlated binomial model. 
Brazilian Journal of Probability and Statistics. 2010;24(1).
18. Chen Z, McGee M. A Bayesian Approach to Zero-Numerator Problems Using 
Hierarchical Models. Journal of Data Science. 2021;6(2):261-268.
19. Samuelson F, Petrick N. Comparing image detection algorithms using resampling. 3rd
IEEE International Symposium on Biomedical Imaging: Nano to Macro, 2006.
20. Davison AC, Hinkley DV. Bootstrap met hods and their applications. Cambridge 
University Press, 1997 
21. Cannon J. Technical Report   An Integrated Analysis of Evaluating 
Subjective Vision, Comfort and Handling for Multifocal Air Optix Habitual Contact Lens Wearers. November 1, 2021.  
22. Whitehead, A. (2002). Meta-analy sis of controlled clinical tr ials (Vol. 7). John Wiley & 
Sons. 
23. Wirth RJ, Edwards MC, Henderson M, et al. Development of the Contact Lens User 
Experience: CLUE Scales. Optom Vis Sci. 2016;93(8):801-808.
24. Bonferroni C. Calculation of the insurance groups of heads. Studies in Honour of 
Professor Salvatore Ortu Carboni. 1935;Rome: Italy:13-60
CR-6477, v 2.0  
Page 76 of 169JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
APPENDIX A: PATIENT REPORTED OUTCOMES (STUDY QUESTIONNAIRES)
CR-6477, v 2.0  
Page 77 of 169JJVC CONFIDENTIAL
35263(&,),&$7,2 )LQDO3URWRFRO-RKQVRQ	-RKQVRQ9LVLRQ&DUH,QF&RQILGHQWLDO 1
CR-6477, v 2.0  
Page 78 of 169JJVC CONFIDENTIALClinical Study Protocol
35263(&,),&$7,2 )LQDO3URWRFRO-RKQVRQ	-RKQVRQ9LVLRQ&DUH,QF&RQILGHQWLDO 2
CR-6477, v 2.0  
Page 79 of 169JJVC CONFIDENTIALClinical Study Protocol
35263(&,),&$7,2 )LQDO3URWRFRO-RKQVRQ	-RKQVRQ9LVLRQ&DUH,QF&RQILGHQWLDO 3
CR-6477, v 2.0  
Page 80 of 169JJVC CONFIDENTIALClinical Study Protocol
35263(&,),&$7,2 )LQDO3URWRFRO-RKQVRQ	-RKQVRQ9LVLRQ&DUH,QF&RQILGHQWLDO 4
CR-6477, v 2.0  
Page 81 of 169JJVC CONFIDENTIALClinical Study Protocol
35263(&,),&$7,2 )LQDO3URWRFRO-RKQVRQ	-RKQVRQ9LVLRQ&DUH,QF&RQILGHQWLDO 5
CR-6477, v 2.0  
Page 82 of 169JJVC CONFIDENTIALClinical Study Protocol
35263(&,),&$7,2 )LQDO3URWRFRO-RKQVRQ	-RKQVRQ9LVLRQ&DUH,QF&RQILGHQWLDO 6
CR-6477, v 2.0  
Page 83 of 169JJVC CONFIDENTIALClinical Study Protocol
35263(&,),&$7,2 )LQDO3URWRFRO-RKQVRQ	-RKQVRQ9LVLRQ&DUH,QF&RQILGHQWLDO 7
CR-6477, v 2.0  
Page 84 of 169JJVC CONFIDENTIALClinical Study Protocol
35263(&,),&$7,2 )LQDO3URWRFRO-RKQVRQ	-RKQVRQ9LVLRQ&DUH,QF&RQILGHQWLDO 8
CR-6477, v 2.0  
Page 85 of 169JJVC CONFIDENTIALClinical Study Protocol
35263(&,),&$7,2 )LQDO3URWRFRO-RKQVRQ	-RKQVRQ9LVLRQ&DUH,QF&RQILGHQWLDO 9
CR-6477, v 2.0  
Page 86 of 169JJVC CONFIDENTIALClinical Study Protocol
35263(&,),&$7,2 )LQDO3URWRFRO-RKQVRQ	-RKQVRQ9LVLRQ&DUH,QF&RQILGHQWLDO 10
CR-6477, v 2.0  
Page 87 of 169JJVC CONFIDENTIALClinical Study Protocol
35263(&,),&$7,2 )LQDO3URWRFRO-RKQVRQ	-RKQVRQ9LVLRQ&DUH,QF&RQILGHQWLDO 11
CR-6477, v 2.0  
Page 88 of 169JJVC CONFIDENTIALClinical Study Protocol
35263(&,),&$7,2 )LQDO3URWRFRO-RKQVRQ	-RKQVRQ9LVLRQ&DUH,QF&RQILGHQWLDO 12
CR-6477, v 2.0  
Page 89 of 169JJVC CONFIDENTIALClinical Study Protocol
35263(&,),&$7,2 )LQDO3URWRFRO-RKQVRQ	-RKQVRQ9LVLRQ&DUH,QF&RQILGHQWLDO 13
CR-6477, v 2.0  
Page 90 of 169JJVC CONFIDENTIALClinical Study Protocol
35263(&,),&$7,2 )LQDO3URWRFRO-RKQVRQ	-RKQVRQ9LVLRQ&DUH,QF&RQILGHQWLDO 14
CR-6477, v 2.0  
Page 91 of 169JJVC CONFIDENTIALClinical Study Protocol
35263(&,),&$7,2 )LQDO3URWRFRO-RKQVRQ	-RKQVRQ9LVLRQ&DUH,QF&RQILGHQWLDO 15
CR-6477, v 2.0  
Page 92 of 169JJVC CONFIDENTIALClinical Study Protocol
35263(&,),&$7,2 )LQDO3URWRFRO-RKQVRQ	-RKQVRQ9LVLRQ&DUH,QF&RQILGHQWLDO 16
CR-6477, v 2.0  
Page 93 of 169JJVC CONFIDENTIALClinical Study Protocol
35263(&,),&$7,2 )LQDO3URWRFRO-RKQVRQ	-RKQVRQ9LVLRQ&DUH,QF&RQILGHQWLDO 17
CR-6477, v 2.0  
Page 94 of 169JJVC CONFIDENTIALClinical Study Protocol
35263(&,),&$7,2 )LQDO3URWRFRO-RKQVRQ	-RKQVRQ9LVLRQ&DUH,QF&RQILGHQWLDO 18
CR-6477, v 2.0  
Page 95 of 169JJVC CONFIDENTIALClinical Study Protocol
35263(&,),&$7,2 )LQDO3URWRFRO-RKQVRQ	-RKQVRQ9LVLRQ&DUH,QF&RQILGHQWLDO 19
CR-6477, v 2.0  
Page 96 of 169JJVC CONFIDENTIALClinical Study Protocol
35263(&,),&$7,2 )LQDO3URWRFRO-RKQVRQ	-RKQVRQ9LVLRQ&DUH,QF&RQILGHQWLDO 20
CR-6477, v 2.0  
Page 97 of 169JJVC CONFIDENTIALClinical Study Protocol
35263(&,),&$7,2 )LQDO3URWRFRO-RKQVRQ	-RKQVRQ9LVLRQ&DUH,QF&RQILGHQWLDO 21
CR-6477, v 2.0  
Page 98 of 169JJVC CONFIDENTIALClinical Study Protocol
35263(&,),&$7,2 )LQDO3URWRFRO-RKQVRQ	-RKQVRQ9LVLRQ&DUH,QF&RQILGHQWLDO 22
CR-6477, v 2.0  
Page 99 of 169JJVC CONFIDENTIALClinical Study Protocol
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
APPENDIX B: PATIENT INSTRUCTION GUIDE 
.  
CR-6477, v 2.0  
Page 100 of 169JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
APPENDIX C: PACKAGE INSERT (APPROVED PRODUCT)
Not applicable.
CR-6477, v 2.0  
Page 101 of 169JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
APPENDIX D: PRESBYOPIC SYMPTOMS QUESTIONNAIRE
CR-6477, v 2.0  
Page 102 of 169JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
APPENDIX G: BINOCULAR OVER REFRACTION
CR-6477, v 2.0  
Page 106 of 169JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
DETERMINATION OF NEAR ADDITION
CR-6477, v 2.0  
Page 108 of 169JJVC CONFIDENTIAL
Title:                          Determination of Near Addition 
Document Type:  
Document Number: Revision Number:  5 
Page 2 of 5 
CR-6477, v 2.0  
Page 110 of 169JJVC CONFIDENTIALClinical Study Protocol 
Johnson & Johnson Vision Care, Inc.
Title:                          Determination of Near Addition 
Document Type:  
Document Number: Revision Number:  5 
Page 4 of 5   
CR-6477, v 2.0  
Page 112 of 169JJVC CONFIDENTIALClinical Study Protocol 
Johnson & Johnson Vision Care, Inc.
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
NEAR LOGMAR VISUAL ACUITY MEASUREMENT PROCEDURE
CR-6477, v 2.0  
Page 114 of 169JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
LENS FITTING CHARACTERISTICS
CR-6477, v 2.0  
Page 117 of 169JJVC CONFIDENTIAL
Title:                          Lens Fitting Characteristics
Document Type:  
Document Number: Revision Number:  6 
Page 5 of 5 
CR-6477, v 2.0  
Page 122 of 169JJVC CONFIDENTIALClinical Study Protocol 
Johnson & Johnson Vision Care, Inc.
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
SUBJECT REPORTED OCULAR SYMPTOMS/PROBLEMS
CR-6477, v 2.0  
Page 123 of 169JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
 DETERMINATION OF DISTANCE SPHEROCYLINDRICAL 
REFRACTIVE ERROR
CR-6477, v 2.0  
Page 125 of 169JJVC CONFIDENTIAL
Title:                           De termination of Distance Spherocylindrical Refractive Error
Document Type:  
Document Number: Revision Number:  5 
Page 2 of 5    
CR-6477, v 2.0  
Page 127 of 169JJVC CONFIDENTIALClinical Study Protocol 
Johnson & Johnson Vision Care, Inc.
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
BIOMICROSCOPY SCALE
CR-6477, v 2.0  
Page 131 of 169JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
DISTANCE AND NEAR SNELLEN VI SUAL ACUITY EVALUATION
CR-6477, v 2.0  
Page 137 of 169JJVC CONFIDENTIAL
Title:                          Distance and Near Snelle n Visual Acuity Evaluation
Document Type:  
Document Number: Revision Number:  5 
Page 2 of 4 
CR-6477, v 2.0  
Page 139 of 169JJVC CONFIDENTIALClinical Study Protocol 
Johnson & Johnson Vision Care, Inc.
Title:                          Distance and Near Snelle n Visual Acuity Evaluation
Document Type:  
Document Number: Revision Number:  5 
Page 4 of 4 
CR-6477, v 2.0  
Page 141 of 169JJVC CONFIDENTIALClinical Study Protocol 
Johnson & Johnson Vision Care, Inc.
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
 DISTANCE LOGMAR VISUAL ACUITY MEASUREMENT 
PROCEDURE
CR-6477, v 2.0  
Page 142 of 169JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
PATIENT REPORTED OUTCOMES
CR-6477, v 2.0  
Page 146 of 169JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
VISUAL ACUITY CHART LUMINANCE AND ROOM ILLUMINATION 
TESTING
CR-6477, v 2.0  
Page 148 of 169JJVC CONFIDENTIAL
Title:                          Visu al Acuity Chart Luminance and Room Illumination Testing 
Document Type:  
Document Number: Revision Number:  4 
Page 2 of 8 
CR-6477, v 2.0  
Page 150 of 169JJVC CONFIDENTIALClinical Study Protocol 
Johnson & Johnson Vision Care, Inc.
Title:                          Visu al Acuity Chart Luminance and Room Illumination Testing 
Document Type:  
Document Number: Revision Number:  4 
Page 3 of 8 
CR-6477, v 2.0  
Page 151 of 169JJVC CONFIDENTIALClinical Study Protocol 
Johnson & Johnson Vision Care, Inc.
Title:                          Visu al Acuity Chart Luminance and Room Illumination Testing 
Document Type:  
Document Number: Revision Number:  4 
Page 4 of 8 
CR-6477, v 2.0  
Page 152 of 169JJVC CONFIDENTIALClinical Study Protocol 
Johnson & Johnson Vision Care, Inc.
Title:                          Visu al Acuity Chart Luminance and Room Illumination Testing 
Document Type:  
Document Number: Revision Number:  4 
Page 6 of 8 
CR-6477, v 2.0  
Page 154 of 169JJVC CONFIDENTIALClinical Study Protocol 
Johnson & Johnson Vision Care, Inc.
Title:                          Visu al Acuity Chart Luminance and Room Illumination Testing 
Document Type:  
Document Number: Revision Number:  4 
Page 7 of 8 
CR-6477, v 2.0  
Page 155 of 169JJVC CONFIDENTIALClinical Study Protocol 
Johnson & Johnson Vision Care, Inc.
Title:                          Visu al Acuity Chart Luminance and Room Illumination Testing 
Document Type:  
Document Number: Revision Number:  4 
Page 8 of 8 
CR-6477, v 2.0  
Page 156 of 169JJVC CONFIDENTIALClinical Study Protocol 
Johnson & Johnson Vision Care, Inc.
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
APPENDIX I: GUIDELINES FOR COVID-19 RISK MITIGATION
CR-6477, v 2.0  
Page 157 of 169JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
PROTOCOL COMPLIANCE INVESTIGATOR(S) SIGNATURE PAGE
Protocol Number and Title: CR-6477 Protocol Title: Ev aluation of a daily disposable silicone hydrogel 
multifocal contact lens in myopes and hyperopes 
Version and Date: 2.0 05 January 2022I have read and understand the protocol specified above and agree on its content.   
I agree to conduct this study according to ISO 14155:2020,
1GCP and ICH guidelines,2the Declaration 
of Helsinki,3United States (US) Code of Federal Regulations (CFR),4and the pertinent individual 
country laws/regulations and to comply with its obligations, subject to ethical and safety considerations. 
The Principal Investigator is responsible for ensuring that all clinical site personnel, including Sub-
Investigators adhere to all ICH2regulations and GCP guidelines regarding clinical trials during and 
after study completion.
I will assure that no deviation from or changes to the protocol will take place without prior agreement 
from the Sponsor and documented approval from the Institutional Review Board (IRB), except where 
necessary to eliminate an immediate hazard(s) to the trial participants.
I am responsible for ensuring that all clinical site personnel including Sub-Investigators adhere to all 
ICH2regulations and GCP guidelines regarding clinical trials during and after study completion. 
All clinical site personnel involved in the conduct of this study have completed Human Subjects Protection Training.  
I agree to ensure that all clinical site personnel involved in the conduct of this study are informed about 
their obligations in meeting the above commitments.
I shall not disclose the information contained in this protocol or any results obtained from this study 
without written authorization.
I have read the suggested guidance provided by JJVCI pertaining to the COVID-19 risk mitigation,
(COVID-19 Work Instruction in the Appendix I of th is protocol). I agree to conduct this study in 
compliance with local, state, governmental guidance for COVID-19 risks. 
Principal 
Investigator:
Signature Date
Name and Professional Position (Printed)
Institution/Site:
Institution/Site Name
Institution/Site Address
CR-6477, v 2.0  
Page 169 of 169JJVC CONFIDENTIAL